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ABSTRACT 
 
Aldolase C is the brain-specific aldolase isoenzyme. In the human brain, aldolase C 
messenger and protein are expressed in a stripe-like pattern in the Purkinje cells of the 
cerebellum, in the inferior olives and in the Goll and Burdach nuclei of the posterior horn 
in the spinal cord. Notwithstanding numerous studies have been conducted on aldolase C 
transcriptional regulation, promoter regions governing brain- and cell-specific expression 
in human are not yet precisely known. 
We analysed transcriptional regulation of human aldolase C gene through in vitro and in 
vivo systems. We previously demonstrated that cAMP increased human aldolase C gene 
expression in PC12 cells through NGFI-B binding to element D in the distal promoter 
region of the gene. Here we demonstrate that NGF up-regulates human aldolase C gene 
expression in PC12 cells. We identified the element E in the distal promoter region as 
responsive to NGF treatment and demonstrated that USF1 binds to this region thus 
mediating transcriptional up-regulation. We also analyzed the transcriptional regulation of 
the human aldolase C gene using transgenic mice as in vivo model. We found that the 
construct pAldC2500-LacZ, containing the cis-elements A, B, C, D and E in the promoter 
region, was able to direct specific, high levels AldC/LacZ hybrid messenger expression in 
the brain of transgenic mice, as well as stripe-like expression in the Purkinje cells of the 
cerebellum. Construct pAldC1500-LacZ, containing elements A, B and C in the proximal 
promoter region, plus element D of the distal region, was able to direct low levels brain-
specific AldC/LacZ and also the stripe-like expression in the Purkinje cell layer. Here we 
analysed three new transgenic mice lines carrying constructs containing different deleted 
promoter regions of human aldolase C gene fused to LacZ reporter gene, in order to further 
point out the role of distal and proximal regions in governing brain-specific and stripe-like 
expression in vivo. Our results indicate that proximal region contains all the elements 
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required for low-levels, stripe-like expression of aldolase C in the cerebellar Purkinje cell 
layer; the distal region is responsible for high-levels, stripe-like expression in the 
cerebellum and in distinct brain areas. 
The second part of this thesis focuses on the functional role(s) of aldolase C protein. To 
improve our knowledge on the canonical glycolytic role of aldolase C, linking isozyme 
structure with function, we produced recombinant aldolases by swapping Isozymes 
Specific Residues (ISRs) from aldolase A to C and viceversa and we analysed their kinetic 
properties. Finally, to shed light on the putative additional functions we have long intended 
aldolase C exert, we started a project aimed to the production of a conditional aldolase C 
knockout mouse.  
7 
 
1. INTRODUCTION 
 
1.1 Aldolase A, B and C genes 
The glycolytic enzyme fructose-1,6-bisphosphate aldolase catalyzes the aldol fission of 
fructose-1,6-bisphosphate (FBP) to dihydroxyacetone phosphate (DHAP) and 
glyceraldehyde- 3-phosphate (G3P) (1, 2). 
There are two distinct classes of aldolase: class I aldolases, which are present in animals 
and higher plants and that use covalent catalysis through a Schiff based intermediate; and 
class II aldolases, which are present in most bacteria and fungi and that require divalent 
metal cations as cofactor. The aldolase in mammals belongs to class I enzymes (1, 2). 
In mammals there are three different isoforms of aldolase, which are encoded by three 
different genes, aldolase A (AldoA), aldolase B (AldoB) and aldolase C (AldoC), located, 
in humans, on chromosome 16 (AldoA), 9 (AldoB) and 17 (AldoC) (3-6). 
About 67% nucleotide sequence identity has been found between aldolase A and aldolase 
C, 63% between aldolase C and B and 68% between A and B. The non-coding sequences 
don‟t show any significative sequence identity (2,7-9). 
These genes derive from a duplication of one ancestral gene and produce three different 
proteins with a high sequence identity, especially in the N-terminus. The C-terminal 
portion of the proteins makes the difference in terms of catalytic and antigenic properties 
(7, 10). 
Aldolase A is ubiquitous but is predominantly expressed in muscle and red blood cells. 
Mutations in this gene have been associated to haemolytic anaemia and myopathy (3, 11, 
12). 
 Aldolase B is involved in the exogenous fructose utilization pathway in the liver; 
mutations in this gene cause fructose-intolerance, a hereditary disorder (1, 5, 13-15).  
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Aldolase C is selectively expressed in adult mammalian brain, particularly in CA3 
hippocampal neurons, in pontine and cerebellar olives, in Goll and Burdach nuclei, in the 
posterior horn of spinal cord, and overall in the Purkinje cells of cerebellum (16).  
The expression of the three proteins is regulated during mammals development. In fetal 
tissues aldolase A is the predominant isoform togheter with the aldolase C. After the birth, 
aldolase A levels decrease to almost disappear in the liver, where aldolase B becomes the 
predominant isoform, and continues to be expressed in all other tissues (2, 5, 7-9, 17, 18). 
Aldolase C rapidly decreases in all tissues except for the brain, where it reaches maximal 
expression levels in the adult. 
The aminoacidic sequences of the mammalian isozymes are highly conserved, exhibiting 
81% sequence identity between aldolases A and C (19). Aldolase B is slightly more 
divergent with ∼70% sequence identity to both aldolases A and C (20). Consistent with 
this sequence similarity, isozymes A and C exhibit comparable kinetic properties. 
Aldolases A and C have evolved to perform the glycolytic reaction, FBP cleavage, more 
efficiently than aldolase B as demonstrated by a 20–30-fold higher kcat (10, 21). 
Conversely, aldolase B cleaves F1P three times more efficiently than aldolase A or C (10). 
In addition, aldolases B and C demonstrate a 10-fold lower Km for glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate, implying that they have evolved to perform 
the gluconeogenic reaction, FBP synthesis, more efficiently than aldolase A (22). 
 
1.2 Aldolase C gene structure in mammals 
The aldolase C gene is present, in mammals, as a single copy per haploid genome and it is 
localized on chromosome 17 in humans. It spans 5198 bp, is shorter than the aldolase A 
and B genes and consists of nine exons: the first is a non-coding exon; the second contains 
12 bp of the 5‟-noncoding region versus 20 bp in the aldolase A gene and 10 bp in the 
aldolase B gene. The coding region is constituted by 1092 bp (364 aa); length and position 
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of coding exons are conserved in human aldolase A and  B genes. A consensus 
polyadenylation signal is present in exon IX. In addition, in the human aldolase C gene, all 
the introns after exon I are shorter than those of  human aldolase A and B genes (3, 4, 19, 
20, 23, 24).  
Aldolase C gene is present on chromosome 10 of rat and on chromosome 11 of mouse. 
Both are constituted by the same number of exons of the homologous human gene and 
show a first non-coding exon of different length.  
Nucleotide sequence of aldolase C gene coding region is conserved among species, 
exhibiting 96% sequence identity between human and rat and 98% sequence identity 
between human and mouse (17).  
  
1.3 Aldolase C gene in inferior organisms 
Aldolase C is highly conserved among species and during the evolution. It is expressed not 
only in mammals like mouse, rat, rabbit and human as an independent gene, but also in 
inferior organisms like lower vertebrates Xenopus laevis, Lampreda and Goldfish and 
invertebrates Drosophila melanogaster and  Caenorhabditis elegans (2, 6, 8, 9, 17, 25-37). 
Xenopus laevis shows three different genes, localized on three different chromosomes, 
coding for aldolase A, B and C. Aldolase C gene structure is very similar to that of human 
and rat. It is composed by 9 exons and encodes for a 363 aminoacids protein. Aldolase C is 
expressed since the first embryonal stages and, in the adult, is mainly present in the brain, 
heart and ovary (25, 26). 
Lampreda shows two distinct genes coding for two proteins, muscolar and non-muscolar. 
The first type shows intermediate characteristics between superior vertebrates aldolase A 
and C and is expressed in skeletal muscle, heart and brain. The second type is equivalent to 
aldolase B of superior vertebrates and is mainly expressed in the liver (28, 29).  
Goldfish shows one independent gene coding for a brain-specific enzyme that seems to be 
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very similar to aldolases A and C of vertebrates rather than aldolase B. Goldfish aldolase 
and human aldolase A, B and C exhibit 83%, 68% and 85% sequence identity, respectively 
(30).  
In invertebrates there are two types of aldolase: neuronal and non-neuronal, which 
originate from a single gene by alternative splicing. The three different aldolase isoforms 
(4α, 4β and 4γ) described in Drosophila melanogaster arise from a single gene by 
alternative splicing of the last exon (exon 4) at the 3‟-end (32). In the invertebrate 
Caenorhabditis elegans, two different coding sequences (cds) have been described: Ce-1 
which shows 60% sequence identity with aldolase B and encodes for a non-neuronal 
aldolase mainly expressed in the gut and pharynx; and Ce-2, which shows about 70% 
sequence identity with vertebrate aldolases A and C and is expressed in neural and 
muscular tissues (neuronal aldolase) (37, 38).  
The high conservation of aldolase C gene during the evolution and its expression limited to 
specific tissues in which aldolase A is co-expressed, suggest the hypothesis of an additive 
role beside that of glycolytic enzyme. 
 
1.4 Human aldolase C gene promoter: in vivo and in vitro studies on transcriptional 
regulation 
Like other brain-specific genes, aldolase C lacks a normal TATA box and a CAAT box is 
present far upstream from its expected position. Multiple transcriptional start sites are 
present in the proximal promoter segment with a major one located -1340 bp upstream 
from the methionine initiation codon. Furthermore, a 100 bp GC-rich region is present just 
upstream from the major transcriptional start site in the mouse, human and rat aldolase C 
genes (8, 29, 39,  40-42). 
Two promoter regions are required for complete aldolase C gene expression in cell lines 
and in transgenic mice (39-42, 43, 44). In the human aldolase C gene promoter, the 
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proximal region, spanning from -164 bp to the major transcriptional start site (+1), has high 
sequence identity with the same region of the mouse and rat genes (69%). In this region 
three cis-acting elements, called A, B and C, have been characterized (40) (see Fig.1, panel 
A). Elements A and B are GC-rich sequences constituted by overlapping motifs that bind 
Sp1 or Sp1-like transcriptional factors and/or members of the Krox20/Krox24 family when 
challenged in vitro with nuclear extracts from neuroblastoma cell lines (SKNBE), rat 
pheocromocytoma cells (PC12) or from rat brain (40, 41, 43, 44). The A and B elements in 
the proximal gene promoter are required to direct low-level, neuronal-specific expression 
of human aldolase C-CAT chimeric constructs in vitro, as we demonstrated in SKNBE and 
PC12 cells (40, 43, 44). These elements are also required to direct low-level, neuronal 
specific expression of rat aldolase C-CAT chimeric constructs in vitro and in vivo (45-48). 
Like elements A and B, element C also binds Sp1 proteins but it seems redundant, being 
not required for transcriptional activation of the human and rat genes in vitro (39-41) (see 
Fig. 1, panel A). 
The distal promoter region of the human aldolase C gene spans from -164 to -1200 bp with 
respect to the major transcriptional start site. This region differs among human, rat and 
mouse aldolase C genes (about 23% sequence identity between rat and human genes). 
Different cis-elements of this region have been characterized through in vitro and in vivo 
studies, using cell lines and transgenic mice brain (41, 43, 44, 48-51). The human aldolase 
C gene distal promoter region, similarly to rat gene, has been split into two functionally 
different regions: a more proximal distal region and a far distal region. The more proximal 
distal region (of about 236 bp), spanning from -164 to -400 bp, contains elements that 
increase by 2.5-fold the transcription of chimeric aldolase C-CAT construct in SKNBE cell 
line with respect to constructs lacking this region (43, 50) In this region, our group 
characterized the "element D" (-203/-196 bp) (see Fig. 1, panel A) containing the 
AGGTCA motif (43, 44, 50). We demonstrated that this element binds the transcriptional 
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activator NGFI-B, a member of a thyroid/steroid/retinoid nuclear receptor gene family (52, 
53). The binding of NGFI-B to the distal promoter region of the human aldolase C gene 
up-regulates the transcription of chimeric aldolase C-CAT constructs in SKNBE cells and 
mediates cAMP-induced transcriptional activation of aldolase C mRNA in PC12 cells (43, 
44) 
The human aldolase C gene is the second gene after mouse 21-OH-ase (54) that has been 
shown to be activated by NGFI-B. The AGGTCA motif is absent from the rat aldolase C 
gene distal promoter region. Thus far, there is no evidence of transcriptional activation of 
mouse or rat aldolase C gene mediated by NGFI-B or cAMP. This supports the hypothesis 
that the transcriptional regulation of the aldolase C gene differs between human and rat 
brain (50). Functional studies, conducted on transgenic mice, demonstrated that large 
genomic fragments (about 5-6 kb) of rat aldolase C gene, are required to direct sustained 
central nervous system-specific (CNS) expression of the chimeric aldolase C-CAT reporter 
gene in transgenic mice (45-48). In particular, the distal region of the rat aldolase C gene 
promoter was found to contain two fragments: an upstream activating sequence (about 0.6 
kb) spanning from -115 to -800 bp, and a far upstream activating sequence spanning from -
0.8 kb to -5.5 kb (see Fig. 1, panel B). Conserved DNA-binding sequences for the 
transcriptional brain-specific activators Brn-1 or Brn-2 and Pax-6, belonging to POU 
homeoproteins, are scattered within the upstream activating sequence. Some of these 
features are conserved in human aldolase C gene far distal promoter region. The presence 
of DNA-binding sequences for the neuronal-specific transcriptional activators Brn-1 and/or 
2 or other POU homeoproteins are typical features of the promoter regions of many 
neuronal genes (55-58). The transcription of most of neuronal-specific genes seems to 
result from a functional synergy between the distal and proximal regulatory elements 
present in the promoter regions. In fact, like other neuron-specific genes, high levels of 
expression of rat aldolase C-CAT constructs in transgenic mice brain requires the 
13 
 
synergism between the 0.6 kb fragment, located in the upstream activating sequence of the 
distal region, the 3.8 kb fragment, located in the far upstream activating sequence, and the 
proximal promoter region, a fragment of about 115 bp, located just upstream from the 
major transcriptional start site. (Fig.1, panel B) (51). Analysis of transgenic mice obtained 
using a larger rat genomic fragment of about 13 kb, containing 6 kb of the 5‟-flanking 
region and 3 kb of the 3‟-flanking region and LacZ as gene reporter, demonstrated that this 
construct contains all the elements sufficient to direct high levels, CNS-specific expression 
of LacZ (59). In contrast, Walther et al. (60) using a construct containing 1.5 kb of the 5‟-
flanking region of the mouse aldolase C gene and 500 bp of the 3‟-flanking region fused to 
LacZ reporter gene, demonstrated that LacZ expression was present only in non-neuronal 
cells, namely astrocytes and pial cells. The same authors, using a larger fragment of the 
mouse aldolase C gene, containing an additional 3 kb of the 5‟-flanking region, identified 
an enhancer element specific to direct LacZ expression in Purkinje cells in a fragment 
spanning from -2.7 kb to -3.6 kb in the promoter region (59-61). All these findings suggest 
that the CNS-specific expression of aldolase C differs between the mouse and rat genes. 
Moreover, these studies failed to identify the promoter regions involved in the expression 
of aldolase C in restricted areas of brain.  
We conducted an in vivo study on transgenic mice in order to identify human aldolase C 
gene promoter regions involved in brain-specific transcriptional regulation (49, 50). We 
used two different constructs containing deleted regions of the human promoter: 
 pAldC-2500-LacZ, which contains 1.2 kb of the human aldolase C promoter region 
(complete promoter region analysed so far), the first intron and the second exon up to the 
methionine (1.3 kb), fused to the methionine of LacZ;  
 pAldC-1500-LacZ, which contains 40 bp of the more proximal distal promoter 
region of the human aldolase C gene, the proximal promoter region (164 bp), the first 
intron and the second exon up to the methionine (1.3 kb), fused to LacZ. 
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We found that the construct pAldC-2500-LacZ was able to direct high-level, brain-specific 
and stripe-like expression of LacZ in adult transgenic mice thereby mimicking the 
endogenous messenger expression (49, 50) (Fig. 2, A-E). 
The construct pAldC-1500-LacZ was able to direct low levels of brain-specific expression 
of LacZ in transgenic mice (49, 50). This construct, containing a short promoter fragment 
of human aldolase C gene (164bp), differently from the proximal promoter region of 
mouse and rat aldolase genes, is able to direct low- levels, stripe-like expression of LacZ in 
the Purkinje cell layer of the cerebellum (Fig. 2, F-G). Moreover, differently from mouse 
and rat genes, the fragment spanning from -164 bp to -1200 bp (distal region) is able to 
direct high levels of LacZ expression in the hippocampal CA3 neurons. 
We concluded  that the transcriptional regulation of the aldolase C gene in the brain and 
cerebellum differs among rat, mouse and human genes and that the 2500 bp promoter 
fragment of human aldolase C gene contains all the elements necessary and sufficient to 
drive brain-specific, regional-specific and cell-specific expression in transgenic adult mice 
brain and cerebellum (49, 50). 
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Figure 1. Organization of the aldolase C gene promoter in human (A) and rat (B): 
(A) Human aldolase C gene promoter. The proximal promoter region is indicated by a 
dotted line. A, B and C cis acting elements are shown to bins Sp1-like factors. The distal 
region is split into a more proximal distal region and a far distal region as indicated by 
dotted arrows. In the more proximal distal region, element D is shown to bind NGFI-B 
factor. In the far distal region the POU binding site, the AT-rich region and the CAAT box 
are indicated. +1 is the major transcription start site and the arrows indicate the multiple 
transcriptional start sites. (B) Rat aldolase C gene promoter (51). Rat proximal region is 
indicated by a dotted line: A/A‟, B and C cis acting elements are boxed. The distal region 
is split in an upstream activating sequence and a far upstream activating sequence. In the 
upstream activating sequence, binding sites for POU homeoproteins (namely Brn-1, Brn-2 
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and Oct-1) are indicated; the AT-rich sequence and a Pax-6 binding-site are also indicated. 
Another Pax-6 binding-site has been evidentiated in the far upstream activating sequence. 
17 
 
 
 
Figure 2. In situ hybridization (A-B) and β-galactosidase (β-gal) (C-G) and calbindin 
(H) immunostaining on paraffin sagittal cerebellar sections (A-H). (A) In situ 
hybridization with mouse specific aldolase C antisense riboprobe. (B) Higher 
magnification of the boxed area indicated in (A) showing groups of aldolase C positive 
Purkinje cells alternating with groups of negative ones. (C) Anti-β-gal immunostaining on 
sections from adult pAldC-2500-LacZ transgenic mice cerebellum. (D, E) Higher 
magnifications of the boxed area indicated in C: two positive Purkinje cells (thick arrows) 
surrounded by negative Purkinje cells (thin arrows) are indicated in E. (F) Anti-β-gal 
immunostaining on sections from pAldC-1500-LacZ transgenic mice cerebellum. (G) 
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Higher magnification of the boxed area indicated in F: note the clusters of Purkinje cells 
expressing β-gal (thick arrows) alternating with clusters of β-gal-negative ones (thin 
arrows). (H) Anti-calbindin immunohistochemistry. Staining throughout the Purkinje cell 
layer shows the integrity of this layer. mol = molecular, p = Purkinje, gr = granular cell 
layers. Scale bars: A, C, F: 200 m; B, D, G, H: 100 m; E: 50 m. 
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1.5 Human aldolase C: messenger and protein expression in mammalian Central 
Nervous System (CNS) 
The 1.75 kb human aldolase C messenger encodes for a 39.5 kDa protein (364 aminoacids) 
(8, 9). 
The functional enzyme is an hetero/homo-tetramer (160 kDa) selectively expressed in 
some CNS regions, like the hippocampus, medulla and amygdaloid nuclei with the highest 
expression level occurring in the cerebellum Purkinje cells. 
(1, 2, 62, 63). 
During mouse brain development, aldolase C messenger appears in the late embryonal 
stage (E 15) in all fetal tissues; after birth, it rapidly decreases in all tissues except for the 
brain, where it reaches maximal expression levels in the adult (64). 
In the last years aldolase C protein became the most extensively studied marker for 
antigenic cerebellar compartmentation (65, 66) being expressed by a subset of Purkinje 
cells in the cerebellum, thus forming parasagittal stripes that are highly reproducible 
between individuals and across species. 
Although the mammalian cerebellar cortex appears histologically uniform, it is subdivided 
rostrocaudally and mediolaterally into a complex array of horizontal zones and parasagittal 
stripes (66-71). This subdivision closely reflects the pattern of afferent and efferent 
connections linking the cerebellum to the rest of the central nervous system CNS (72, 73). 
The cerebellar vermis can be subdivided into four horizontal zones based on differential 
protein expression: the anterior zone (AZ; lobules I–V), the central zone (CZ; lobules VI–
VII), the posterior zone (PZ; lobules VIII–dorsal IX), and the nodular zone (NZ; ventral 
lobule IX–lobule X) (71, 74, 75). Each horizontal zone is further subdivided into 
parasagittal stripes.  
Aldolase C is expressed in a stripe-like way only in the cerebellar AZ and PZ. 
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Aldolase C stripes of Purkinje cells are referred to as P1+ to P7+ (numbered in the figure 3 
as 1–7 for clarity) (76) from the midline laterally, and the intervening aldolase C – stripes 
(beige in the figure) are numbered with reference to the neighbouring aldolase C + stripe 
(Fig. 3) (64, 76). 
During mouse brain development, aldolase C protein is not expressed at all until postnatal 
day 5 (P5), then, from P5-P7 aldolase C is found only in the posterior lobe vermis, with 
immunoreactive Purkinje cells in lobules X, IX, and VIII but not elsewhere; from P7-P12 
most Purkinje cells in the vermis become aldolase C + (initially described in rats by 
Leclerc et al. 1988) (77); from P12-P15 immunoreactivity also appears in the hemispheres 
so that almost all Purkinje cells now are aldolase C +; and finally, from P15-P25 aldolase 
C is gradually suppressed in those Purkinje cells that are negative in the adult until the 
mature pattern of parasagittal compartments is revealed selectively in lobules I-V and VIII-
IX (AZ and PZ) (78, 79). 
Stripe-like expression is a common feature of genes selectively expressed in the 
cerebellum (77, 78). The stripe-like expression of aldolase C in the Purkinje cells of mouse 
cerebellum was first reported by Anh and Hawkes (64, 80) which called aldolase C 
"zebrin"; subsequently, our group described the stripe-like expression of the aldolase C 
mRNA and protein also in the human cerebellum (81). 
Our group was able to draw-up a detailed map of aldolase A and aldolase C mRNA and 
protein expression in different areas of the human brain and cerebellum.  
We found that, in human CNS, Aldolase A mRNA, unlike aldolase C, is strongly 
expressed in all areas of the CNS. Particularly, aldolase A protein is expressed in  neurons 
of the supraorbital gyrus and in neurons from frontal and temporal lobes, in the cytoplasm 
of pyramidal neurons near Rolando‟s sulcus. Aldolase C is absent from these areas. In the 
olives, aldolase A is expressed in neurons of the superior and inferior olives. In the same 
areas, aldolase C protein is expressed only in the inferior olives and with a stripe-like 
21 
 
distribution in the neuropil. In the cerebellum the aldolase A protein is expressed at low 
levels throughout the Purkinje cell layer (Fig. 4, A). 
Aldolase C protein is expressed in an antero-posterior gradient. It is present in some 
neurons near Rolando‟s sulcus and in the neurons near the calcarine scissure in the 
occipital cortex but is absent from the motoneurons in the supraorbital cortex. Maximum 
expression occurres in the Purkinje cells of the cerebellum as well as in mouse and rat. 
Finally, aldolase C stripe-like expression pattern, has been revealed in humans, not only in 
the Purkinje cells of the cerebellum (Fig. 4, B-D), but also in the inferior olives and in Goll 
and Burdach nuclei of the posterior horn in the spinal cord (Fig. 4, E-F). Differently from 
aldolase C, aldolase A, is not expressed in stripes, therefore, stripe-like expression is an 
aldolase C-specific feature (50, 81). This peculiar stripe-like distribution of aldolase C 
protein in specific areas of CNS where aldolase A is co-expressed, supports the hypothesis 
that aldolase C could exert additive functions besides its glycolytic role.  
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Figure 3. Aldolase C and cerebellar cortical organization. 
The mouse cerebellar cortex is divided into horizontal zones, and each zone is subdivided 
into parasagittal stripes. Zones and stripes are clearly seen in the expression pattern of 
aldolase C. The distribution of Purkinje cells immunoreactive to aldolase C in the 
cerebellum of the adult mouse, seen from anterior (top panel), dorsal (middle panel) and 
posterior (bottom panel) views reveals a complex cytoarchitecture comprising four 
horizontal zones in the vermis and in both hemispheres: the striped anterior zone (AZ) and 
the posterior zone (PZ) alternate with the uniformly aldolase C immunopositive central 
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zone (CZ) and nodular zone (NZ; partly reflected out from beneath lobule IX). Aldolase 
C+ stripes of Purkinje cells are referred to as P1+ to P7+ from the midline laterally, and the 
intervening negative stripes (beige in the figure) are numbered with reference to the 
neighbouring (medial) positive stripe. Lobules in the vermis are indicated by Roman 
numerals. 
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Figure 4. Aldolase A and aldolase C immunostaining on coronal sections from human 
anterior cerebellar cortex (A-D) and from spinal cord at the posterior horn (E-F). 
(A) Purkinje cells expressing aldolase A (thick arrows). (B) Stripe-like expression of 
aldolase C protein in the Purkinje cells (thick arrows indicate aldolase C positive cells). 
(C) Higher magnification of the box indicated in B: note two positive aldolase C-
expressing cells surrounding one negative. (D) Aldolase C protein expression in the 
cytoplasm and in the dendrites of positive Purkinje cells (thick and thin arrows, 
respectively). (E) Goll (G) and Burdach (B) nuclei in the spinal cord: aldolase C is strongly 
expressed in the Goll and Burdach nuclei. (F) Higher magnification of the box indicated in 
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E: note the stripe-like distribution of aldolase C protein in the neuropil. Scale bars: A, C, D 
and F: 100 μm; B: 500 μm. E: the section contains the whole posterior part of the spinal 
cord: the image is magnified 5 times with respect to the slide. mol, p and gr, molecular, 
Purkinje cell and granule cell layers, respectively. a, anterior part; p, posterior part.  
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1.6 Aims 
The molecular basis of the stripe-like distribution of aldolase C in specific areas of CNS 
are still unknown. This peculiar expression pattern led us to hypothesize aldolase C 
exerting moonlight functions besides its glycolytic role. To date, there aren‟t any published 
disease-causing mutations in this gene. It is also unclear why the aldolase C gene is 
acquired during evolution in addition to the other two aldolases and especially in addition 
to aldolase A that is co-expressed with aldolase C in such areas of CNS.  
My PhD thesis project could be split into two main parts: 
A) The study of transcriptional regulation of human aldolase C gene as a model useful to 
understand the complex regulatory mechanisms of genes selectively expressed in CNS through: 
 in vitro systems, in order to point out promoter region(s) involved in transcriptional 
activation during neuronal differentiation induced by NGF in PC12 cells; 
 in vivo systems, in order to identify human aldolase C gene promoter regions 
responsible for its brain-specific and stripe-like expression in Purkinje cell layer of 
transgenic mice. 
B) The study of the functional role of aldolase C protein in order to improve our 
knowledge on its hypothetical additional functions: 
 in vitro, through the production of chimeric aldolases AC and CA in which isozyme 
specific residues (ISRs) have been switched from aldolase A to C and viceversa. The 
analysis of kinetic parameters of these recombinant enzymes has been performed in order 
to explore the role of conformational dynamics in catalytic mechanisms; 
in vivo, through the production of aldolase C conditional knockout mice as a model to 
investigate for putative additional functions of aldolase C protein besides its glycolytic 
role. 
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2. MATERIALS AND METHODS 
 
2.1 Materials 
Reagents were provided by Sigma (St.Louis, USA), Carlo Erba Reagenti (Milano, Italia), 
Serva (Heidelberg, FRG), Amersham-Pharmacia Biotech. (England), Bio Rad Lab. (CA, 
USA), Difco (Becton Dickinson , MD, USA). 
Kits were provided by Amersham-Pharmacia Biotech (England), Qiagen Inc. (Valencia, 
USA), Stratagene (La Jolla, USA), Takara Biomedicals Group (Japan), Vector 
laboratories, (USA), Roche Molecular Biochemicals (Germany), Gibco BRL (Life 
technologies, Bethesda, USA).  
Restriction and modification enzymes were provided by Roche Molecular Biochemicals 
(Mannheim, Germany), Promega Corporation (Madison, Winsconsin, USA), Invitrogen 
(Groningen, Netherlands). 
Enzymes for RT-PCR, PCR e Real-Time PCR were from Invitrogen (Italy- MI). 
Oligonucleotides used as primers for PCR and sequence analysis were provided by Boston 
University Core Sequencing Facility and by CEINGE (Biotecnologie Avanzate s.c.ar.l., 
Napoli, Italia). 
Vectors used for recombinant constructs preparation were provided by Stratagene (La 
Jolla, USA), Clontech Lab. Inc. ( Palo Alto, CA, USA). 
B6D2F1 and CD1 mice strains were from Charles River (Italy). 
C57black6 (C57bl/6) mice strains were from EMBL (European Mouse Biology 
Laboratory, Monterotondo, Rome). 
Tubes and plastic materials were from Falcon (Becton Dickinson, UK). 
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2.2 Generation of reporter constructs and site-directed mutagenesis 
Constructs 1190-chloramphenicol acetyltransferase (CAT), 420-CAT, and 164-CAT 
were made as indicated in Buono et al. 1993 (40), and 208-CAT was made as indicated in 
Buono et al. 1997 (43). The insert of 260-CAT construct was obtained by PCR using as 
template the 420-CAT clone, containing 420 bp of the promoter region of human aldolase 
C gene. The oligonucleotide 260 BamHI F 5‟-ACTAAGCTGGATCCCCAGCATC-3‟ (-
277/-256) (+1 being the major transcription start site) containing the BamH1 restriction site 
and the oligonucleotide 260 PstI R 5‟-CAAACAGATGAGGCTGCAGCCCT-3‟ 
(+28/+10) containing the PstI site, were used as primers. The reaction was carried out in 50 
l buffer containing 0.2 mM dNTPs, 100 ng of primers described above, and 5 units of 
TaqI polymerase (Invitrogen, Italy). The PCR products were digested by BamH1/PstI, 
purified from agarose gel, and then cloned in BamH1/PstI sites, upstream the CAT reporter 
gene in the pEMBL-8-CAT expression vector (59). The construct 260*-CAT was 
obtained by site-directed mutagenesis with the Quick-Change site-directed mutagenesis kit 
(Stratagene)  using the the construct 260-CAT as template. The site-directed mutagenesis 
was performed according to the manufacturer‟s instructions and using the oligonucleotides 
260* mut (F) 5‟-TGGCAGAAATGAACGCTGCAGCAT GGCCAGGCTCCC-3‟ and its 
complement as reverse (R) (-216/-181) which carry the restriction site PstI replacing the 
element D.  
The constructs pTK-E1-CAT and pTK-E3-CAT contain one (Con1.USF1 F/R ) and three 
tandem copies (Con3 USF1 F/R)  of the oligonucleotide spanning from -216 to -181 in the 
promoter of human aldolase C gene, containing the specific element E binding site: 
E1- AAGCTTGTGCCCGGCACGTGGTAAAGGGATTGGGTACC  
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E3-AAGCTTGTGCCCGGCACGTGGTAAAGGGATTG-
GTGCCCGGCACGTGGTAAAGGGATTG-
GTGCCCGGCACGTGGTAAAGGGATTGGGTACC 
These oligonucleotides were designed starting and ending with the restriction sites for 
HindIII (5‟) and KpnI (3‟) restriction enzymes (shown in red) to be used for the cloning in 
pTK-CAT vector. 
  
2.3 Cell coltures 
PC12 pheochromocytoma cell line was cultured in Petri plates (Ø 100 mm and 60 mm, 
Sarstedt, CELL PLUS) . Cells were grown in 10 ml of RPMI colture medium containing 
10% horse serum (HS), 5% fetal bovine serum (FBS) and a mixture of 1% penycillin and 
streptomycin, at 37°C in an atmosphere with 5% CO2 and 95% air. Cells were subcultured 
every 2-3 days and induced to neuronal differentiation by adding 100 ng/ml Nerve Growth 
Factor 7S (NGF 7S) (GIBCO) at different times. SKNBE cells were grown on glass 
coverslips  in RPMI medium containing 15% fetal bovine serum, 1% penicillin and 
streptomycin at 37° C and with an atmosphere of 5% CO2, 95% air, and subcultured 1:3 
every 3 days. 
 
2.4 Transient transfection and CAT assay 
Transfections were performed using the Lipofectamine 2000, according to the 
manufacturer‟s instructions (Invitrogen, life technologies).  
PC12 cells were seeded at 4 x10
5
 cells/60 mm Petri dish and grown overnight. Co-
transfections were performed with different aldolase C promoter-CAT constructs, 
containing serial deletions of the promoter region or site-directed mutation of the NGFI-B 
trascription factor (-260*-CAT) binding site, and with pRL-LUC plasmid as internal 
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standard. pRL-LUC is a plasmid expressing the Renilla luciferase gene used to normalize 
for differences in the transfection efficiency.  
pEMBL8-CAT and CMV-CAT were used as negative and positive controls, respectively.  
Cells were co-transfected  with 2 g of each construct containing different deleted regions 
of human aldolase C gene promoter and 1 g of pRL-LUC plasmid as internal standard. 6 
hours  after the transfection, the cells were stimulated with 100 ng/ml NGF for 3 days. 
Transfections were performed in duplicate and repeated three times.  
After NGF treatment, cells were washed with PBS, harvested with TEN (40 mM Tris, 1 
mM EDTA, 150 mM NaCl) and centrifuged at 4°C for 5 minutes. Cell pellets were 
resuspended in 50 µl of  250 mM Tris pH 7.8,  subjected to three “freeze and thaw” cycles 
in order to lyse cell membranes and, finally, centrifuged for 10 minutes at 4°C. The 
supernatant obtained, containing proteic extracts was aliquoted and kept at -80°C. Proteic 
extracts were successively used for the CAT assay. CAT assays were performed as 
described by Gorman et al. (82): 
 Cell extracts amounts were added to a mixture containing  55 µl of Tris 0,25 M pH 
7.8 and 1µl of 
14
C- chloramphenicol and the reaction run at 37°C for 5‟; 
 20 µl of acetyl-CoA 4 mM (3,5 mg/7ml in 0,25M di Tris pH 7.8) were added to the 
mixture and the reaction run at 37°C for 5‟; 
 Acetylated and non-acetylated forms of chloramphenicol produced during the 
reaction were extracted with 800 µl of ethyl acetate and centrifuged for 3-5 minutes;  
 The supernatant, which contains acetylated and non-acetylated forms of 
chloramphenicol, was let evaporate in a centrifuge under vacuum (speed-vac) to 
reduce the volume;  
 Pellets were resuspended in 15 µl of ethyl acetate and loaded on a thin-layer 
chromatographic (TLC) sheet (Polygram SIL-G - 0,25 mm) placed in a chamber with 
a mixture of chloroform and methanol (39:1) as solvent in the bottom;  
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 The samples were allowed to migrate up the TLC sheet so that the unacetylated 
chloramphenicol was separated from its mono- and bis-acetylated derivates;   
 The silica sheet was exposed to a Phosphoroimager storage phosphor screen in an 
appropriate cassette for 3 hours;  
 The screen was finally scanned using a Storm-840 instrumentation; 
 The intensity of radioactive signals was analysed by using the ImageQuant  
programme. 
Luciferase activity in cell extracts was measured essentially according to de Wet et al. (83) 
using a Berthold Blolumat LB 9501 luminometer. CAT activity in the extracts of 
transfected cells was normalized to the luciferase activity (RLU, relative luciferase units) 
determined by the Dual-Luciferase Reporter Assay System (Promega), according to the 
manufacturer‟s instructions. 
 
2.5 Nuclear extracts and Electro Mobility Shift Assays 
Nuclear extracts from PC12 cells were obtained as described in Dignam et al. (84) with 
some modifications. Cells were washed in PBS 1X (phosphate buffered saline) (Gibco), 
centrifuged, resuspended and syringed in the solution I (10 mM Hepes pH 7.9, 10 mM 
KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM PMSF, 0.1 mM DTT). The nuclear extracts 
pellet was then resuspended in the solution II which contains, differently from solution I, 
400 mM NaCl instead of KCl and 5% glycerol. Samples were incubated on ice for 30 
minutes and centrifuged at 14.000 rpm for 40 minutes at 4°C. The supernatant was finally 
aliquoted and kept at -80°C. 
EMSA were performed as described in Buono et al. (43), using 4 g of nuclear extracts 
from PC12 cells. 3 g of poly (dI/dC) were added to each sample as non-specific 
competitor. 
The following oligonucleotides were used: 
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 L1 (-211/-186 bp in the promoter of human aldolase C gene), which contains the 
specific binding site for NGFI-B (set in bold type) (43):  
5‟-TGAACGCAAGGTCATGGCCAGGCTCC-3‟ 
 21-OHase (-79/-62 bp in the promoter of 21-OHase mouse gene) which binds 
NGFI-B to the sequence set in bold type (54): 
5‟-TGAAGCAAAGGTCAGAG-3‟ 
 BRD (-245/-211 bp in the promoter of human  aldolase C gene), which contains the 
consensus sequences for NGFI-B (shown in bold) and for USF1 (shown in bold-
italic):  
5‟GTGCCCGGCACGTGGTAAAGGGATTGTGGCAGAAATGAACGCAAGGT
CATGG-3‟   
 BRD-L1 (-245/194 bp in the promoter of human  aldolase C gene), which contains 
the consensus sequence for USF1 (shown in bold-italic):  
5‟-GTGCCCGGCACGTGGTAAAGGGATTGTGGCAGAAA-3‟  
 USF1, which contains the consensus sequence for USF1 (set in bold)  
5‟ -CACCCGGTCACGTGGCCTACACC-3‟ 
 NF-I, which contains the consensus sequence for NF-I (set in bold)  
5‟-TTTTGGATTGAAGCCAATATGATAA-3‟ 
 Sp1, which contains the consensus sequence for Sp1 (set in bold)  
5‟-ATTCGATCGGGGCGGGGCGAGC-3‟ 
The probes used for EMSA were labelled as single strand (3 pmol) by using the “Random 
Primers DNA Labeling System” kit according to the manufacturer's protocol (Invitrogen). 
The single strand probes were then annealed with their complementary strand as described 
in Buono et al. 1997. The labelled double strand probes were finally purified by Sephadex-
G50 column chromatography (Pharmacia Biotech, Piscataway, NJ, U.S.A.). 
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The competition analysis was performed using unlabelled oligonucleotides BRD, L1 and 
USF1 as specific competitors and the oligonucleotides Sp1 and NF1  as non-specific 
competitors. Supershift analysis was conducted using 2, 4 and 6 g of anti-USF1 specific 
polyclonal antibody (Santa Cruz Biotechonogy, Inc., California) and 6 g of non immune 
IgG as irrelevant polyclonal antibody. Dephosphorylation assay was conducted using 1 and 
2,5 units of CIP (Calf Intestinal Phosphatase, Promega Italia) and 2,5 units of inactivated 
CIP as negative control for 1h at 37°C.  
After the incubation of cold probes (self and non-self competitors), binding solution and 
poly (dI/dC) with nuclear extracts for 20 minutes at 25°C, the hot probes were added 
(30000 cpm) and the reaction was continued at room temperature for 10 minutes.  
The complex DNA-protein was separated from the unbound DNA through electrophoresis 
in 0.5% Tris-borate EDTA buffer (44 mM Tris-HCl, 44 mM boric acid, 12.5 mM EDTA, 
pH 7.5) on 4% (w/v) non-denaturing polyacrylamide gel, The gel was subsequently dried 
and autoradiographed. 
 
2.6 Chromatin Immunoprecipitation (X-ChIP) 
SKNBE neuroblastoma cells were grown on glass coverslips  (12x10
6
 cells/well) as 
described in the paragraph 2.3. The crosslinking of proteins to DNA was performed by 
adding formaldehyde to cell culture media at a final concentration of 1%. Fixation 
proceeded at room temperature for 10 minutes and was stopped by the addition of glycine 
to a final concentration of 0.125 M. Chromatin immunoprecipitation was performed as 
described (85): 
cells were washed 2 times with 6 ml of PBS 1X and centrifuged at 3.000 rpm for 30 
minutes at 4°C. Pellets were resuspended in 1,5 ml of cell lysis buffer (5 mM PIPES pH 
8.0, 85 mM KCl, 0,5% NP40, 1mM PMSF, 1/1000 protease inhibitors cocktail). Cell lysate 
was centrifuged at 5.000 rpm for 5 minutes at 4°C. Pellets were resuspended in 300 l 
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nuclei lysis buffer (50 mM Tris HCl pH 8.0, 10 mM EDTA, 0,8% SDS, 1 mM PMSF, 
1/1000 protease inhibitors cocktail) and put on ice for 10 minutes. The DNA linked to the 
proteins was sonicated 6 times for 30 seconds, transferred in 1,5 ml tubes, centrifuged at 
14.000 rpm for 10 minutes at 4˚C. The supernatant was diluted up to 1 ml with a Dilution 
Buffer (0,01% SDS, 1% TRITON X-100, 0.5 mM EGTA; 10 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1/1000 protease inhibitors cocktail), and kept at a -80˚C. 
Chromatin aliquots were subdivided into three fractions and 20l of protein A/G Plus-
Agarose (Santa Cruz) were added to each fraction. After an incubation for 2 hours at 4°C 
(preclearing reaction), samples were centrifuged and the supernatants were incubated O.N. 
at 4
o
C with rotation: the first fraction was incubated with 3-5 μg of the specific anti-USF1 
antibody, the second and the third fraction were incubated with no antibody (called “No 
Ab”) and with rabbit IgG, respectively, as negative controls. 20l of protein A/G Plus-
Agarose (Santa Cruz) were added to each sample and let rotate for 3-4 hours at 4°C. 
Precipitates, beads and supernatant were separated by centrifugation at 13.000 rpm for 1 
minute at room temperature. The precipitates were washed 5 times with 1 ml of RIPA 
Buffer, 1 time with LiCl Buffer (0,25 M LiCl, 0,5% NP-40, 0,5% Na- Deoxycolate, 1 mM 
Na-EDTA, 10 mM Tris-HCl pH 8.0) and 1 time with TE Buffer (10 mM Tris-HCl pH 8, 1 
mM EDTA).  
Finally, the precipitates were resuspended in 100 l of TE. Immunoprecipitated chromatin 
aliquots were incubated with 1 g of RNase at 65°C O.N. 
To purify immunoprecipitated DNA, samples were added of 0,5% SDS, 500 mg/ml 
Proteinase K and incubated for 4 hours at 50°C. Successively, samples were centrifuged at 
14.000 rpm for 2 minutes at 4°C to remove the resin and treated with an equal volume of 
phenol-chlorophorm - Tris pH 8.0. 
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The DNA extraction was repeated by adding an equal volume of Tris-HCl pH 8.0 1 M to 
the organic phase. The DNA was precipitated with 100g/ml glycogen as a carrier agent. 
Finally, both the specific immunoprecipitated DNA and the No Ab fraction were 
resuspended in 30 l of water. 
Approximately 50 ng of immunoprecipitated DNA were used for PCR reactions producing 
a final fragment of ~100 bp. Specific oligonucleotides, mapping in the promoter of human 
aldolase C gene, were designed as described below: 
-319 F:  5‟- CCACCTACTCAACCTGTTGTT-3‟ 
-201 R:   5‟-TGGCTGTTAGGGACTGCCC-3‟ 
PCR reaction were carried out in a final volume of 50l and performed in a Biorad 
Thermal Cycler by using the following scheme repeated for 30 cycles: 
 Denaturation   94° C x 45‟‟ 
 Annealing   60°C x 30‟‟  
 Polymerization  72°C x 15‟‟  
1/10 of the PCR product was analysed by agarose gel electrophoresis to verify the effective 
amplification.  
 
2.7 Western Blot 
Nuclear and cytosolic extracts from PC12 cells wt and treated with NGF were obtained 
using “Qproteome nuclear protein kit” according to the manufacturer's protocol (Qiagen). 
The same quantities of protein extracts (40 g) were separated on a 15% SDS-acrylamide 
gel (SDS-PAGE), transferred on a nitrocellulose membrane (Amersham Pharmacia 
Biotech) and checked by Ponceau S staining to determine equal loading. The coloured 
filter was preincubated with milk 10% in PBS/0.1% Tween-20 for 1 hour, and then 
incubated with a specific polyclonal anti-USF1 antibody (SantaCruz Biotechnology, 
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1:1000). After the incubation with a anti-rabbit secondary antibody coniugated with 
peroxidase (Amersham Pharmacia Biotech), immunoreactive bands were revealed by 
chemiluminescence (ECL). Polyclonal anti-cyclin A and anti--tubulin antibodies were 
used as control for nuclear and cytosolic extracts respectively. 
 
2.8 Immunofluorescence assays  
PC12 cells were grown on chamber-slides polilysine pre-treated (Nalgene Nunc) 
(20.000/well, 270 µl of fresh RPMI medium) and transfected with recombinant constructs 
by using Lipofectamine 2000 (Invitrogen), as described in the paragraph 2.8 of Materials 
and Methods. One day after the transfection some wells were added with NGF 100 ng/ml 
and the treatment continued for 3 days. Subsequently, cells were fixed with cold 3% 
paraformaldehyde in PBS, washed with PBS, and permeabilized with 0.2% Triton X- 100 
in PBS. Blocking was the next step: cells were incubated with 200 µl of a solution 
containing PBS 1X, BSA (bovine serum albumine) 2%, FBS 10% and Triton 0.1% for 1 
hour at room temperature. Cells were then incubated with anti-USF1 antibody 1:100 
diluted (Santa Cruz) in the blocking solution for 3 hours at room temperature. The second 
incubation was conducted in the dark for 1 hour with fluorescent secondary antibody rabbit 
anti-FITC (fluorescein isothiocyanate) 1:100 diluted. Finally, the last incubation was 
performed for 5 minutes with DAPI nuclei stain solution 0.05 g/ml (6-Diamidino-2-
phenylindole dihydrochloride). Coverslips were then washed in PBS, mounted on a glass 
microscopic slide (BDH) with fluorescence mounting medium  (Dako) and examined using 
a Zeiss Axiovert 200 microscope equipped with the confocal laser system LSM 510 
META. Image processing was performed with Adobe Photoshop software. 
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2.9 Cloning and DNA preparation for microinjection 
The transgenic construct pAldC-1580-LacZ was obtained by mutagenesis of the original 
construct pAldC-2500-LacZ (49). The Quick Change site-directed mutagenesis kit 
(Stratagene) was used to create an extra SalI restriction site (underlined) in the position – 
280 bp. 
The sequences of  oligonucleotides used for the site-directed mutagenesis are: 
Wt-Fw: 5‟- GCTTAATCCCCAGCATCCAGCAAGTGCCCGGCACGTGG -3‟ 
Mut-Fw: 5‟- GCTTAATCCCCAGCGTCGACCAAGTGCCCGGCACGTGG -3‟ 
Wt-Rev: 5‟- CCACGTGCCGGGCACTTGCTGGATGCTGGGGATTAAGC -3‟ 
Mut-Rev: 5‟- CCACGTGCCGGGCACTTGGTCGACGCTGGGGATTAAGC-3‟ 
The fragment SalI-SalI (-1200 bp/-280 bp) was removed by digestion and the remaining 
deleted construct was purified from agarose gel by electroelution, ligated and 
recircularized by using the T4 Ligase (Invitrogen). 
In the same way the construct pAldC-1464-LacZ was obtained by mutagenizing the 
original construct pAldC-2500-LacZ and creating an extra SalI restriction site (underlined) 
in the position -164 bp. 
The sequences of  oligonucleotides used for the site-directed mutagenesis are: 
Wt-Fw: 5‟-AGGTGGGAGGGCAGTCCCTAACAGCCACGGATGCCTGGG-3‟ 
Mut-Fw:5‟AGGTGGGAGGGCAGTCGACAACAGCCACGGATGCCTGGG-3‟ 
Wt-Rev: 5‟-CCCAGGCATCCGTGGCTGTTAGGGACTGCCCTCCCACCT-3‟ 
Mut-Rev: 5‟-CCCAGGCATCCGTGGCTGTTGTCGACTGCCCTCCCACCT-3‟ 
The fragment SalI-SalI (-1200 bp/-164 bp) was removed by digestion and the construct 
was purified from agarose gel by electroelution, ligated and recircularized as described 
above. 
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The transgenic construct pAldC-2336-LacZ was obtained by a double mutagenesis of the 
original construct pAldC-2500-LacZ. The first mutagenesis was performed to create an 
extra NruI restriction site (underlined) in position -164 bp. 
The second mutagenesis created another NruI restriction site just upstream the major 
transcriptional start site (+1).  
The sequences of  oligonucleotides used for the first site-directed mutagenesis are: 
Wt-Fw: 5‟-GTGGGAGGGCAGTCCCTAACAGCCACGGATGC-3‟ 
Mut-Fw: 5‟-GTGGGAGGGCAGTCGCGAACAGCCACGGATGC-3‟ 
Wt-Rev: 5‟-GCATCCGTGGCTGTTAGGGACTGCCCTCCCAC-3‟ 
Mut-Rev: 5‟-GCATCCGTGGCTGTTCGCGACTGCCCTCCCAC-3‟ 
The sequences of  oligonucleotides used for the second site-directed mutagenesis are: 
Wt-Fw: 5‟-GCCCCCGGAGGAGTCACGTAGCTCTGCGACAT-3‟ 
Mut-Fw: 5‟-GCCCCCGGAGGAGTCGCGAAGCTCTGCGACAT-3‟ 
Wt-Rev: 5‟-ATGTCGCAGAGCTACGTGACTCCTCCGGGGGC-3‟ 
Mut-Rev: 5‟-ATGTCGCAGAGCTTCGCGACTCCTCCGGGGGC-3‟ 
The proximal promoter region (164 bp) was removed by NruI digestion and the remaining 
deleted construct was purified from agarose gel by electroelution, ligated and 
recircularized by using the T4 Ligase (Invitrogen). 
All oligonucleotides were synthesized by CEINGE, Naples, Italy.  
Polymerization reaction were set up in 50 l final volume containing 20 ng of DNA 
template, 1 l of Pfu turbo DNA polymerase (2,5U/ l), 5 l of 10x Reaction buffer, 125 
ng of Forward and Reverse primers and 1 l of dNTP mix. PCR reactions were performed 
as follows: 
1 step:   
 Denaturation  95°C x 30” 
12-18 cycles:   
39 
 
 Denaturation  95°C x 30” 
 Annealing  68°C x 1‟ 
 Extension  72°C x 2‟ 
Finally, methylated DNA template and hemimethylated hybrid products (DNA 
template/target sequence) were digested by adding the DpnI restriction enzyme. E.Coli 
bacterial cells were transformed with recombinant mutated plasmids, grown and then the 
plasmids were purified over a Qiagen column maxiprep (49). The sequences were verified 
by digestion and automated sequencing. After removal of vector sequences by Sal/NotI 
digestion, the microinjection fragments were purified from agarose gel by electroelution 
and phenol:chloroform extraction, resuspended in TE buffer at 2 ng/l and microinjected 
into 1-cell fertilized eggs. 
 
2.10 Generation and identification of transgenic mice 
Single-cell embryos were harvested from the hybrid B6D2F1 mouse strain (Charles River). 
The purified AldC/LacZ fragments were microinjected into the embryonic male pronuclei 
and surviving embryos were transferred into the oviducts of pseudopregnant CD-1 foster 
mothers (Charles River) essentially as described in Hogan et al. (86). Transgenic founders 
and offspring were identified by Southern blot using a [32-P]ATP random-primed LacZ 
cDNA probe. Three independent stabilized mouse lines were obtained for each construct:  
 Construct pAldC-1464-LacZ – lines  H5, H62, H69; 
 Construct pAldC-1580-LacZ – lines I36, I37, I40; 
 Construct pAldC-2336-LacZ – lines N8, N10, N22.  
The Animal Experimentation Ethics Committee of the National Institute for Cancer 
Research of Genoa approved all the animal studies. 
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2.11-Galactosidase assay 
-Galactosidase (-gal) activity was assayed in intact and sagittal section of brains and in 
body parts of adult transgenic mice obtained from the three constructs; sagittal plate 
sections were identified according to Altman and Bayer (87). Mice were sacrificed by 
cervical dislocation. Brains were washed in PBS 1X, fixed in 2% paraformaldehyde for 1 
h, and then rinsed and incubated overnight at 30 °C in phosphate-buffered saline (PBS) 
containing 400 mg/ml X-Gal substrate (5-bromo-4-chloro-3-indolyl-b-D-galactoside), 4 
mM potassium ferricyanide, 4 mM MgCl2, and 0.1% Nonidet P-40 as described in Smeyne 
et al. (88) and in Oberdick et al. (89). Brains were successively washed in PBS 1X for 
three times (15‟/wash) and then observed under the optic microscope (Zeiss). 
 
2.12 Immunohistochemistry 
Formalin-fixed paraffin-embedded nervous tissue blocks were prepared from transgenic 
mice brains. Serial horizontal and sagittal 7-10 μm sections were cut from the formalin-
fixed tissue blocks, dewaxed in xylene analogs (Bio-Clear Bio-Optica, Milan, Italy) and re-
hydrated with graded ethanol concentrations. These sections were incubated for 45 minutes 
at 97°C in citrate buffer pH 6.0 (DAKO, S2369) in order to reduce immunogenicity. 
Endogenous peroxidase activity was blocked by immersing slices in 3% hydrogen 
peroxide methanol for 10 minutes. Aspecific antigen sites were blocked by incubating at 
room temperature for 30 minutes with background reducing components (DAKO).  
Three contiguous brain sections were incubated at room temperature for 1 hour with 
primary antibodies in the following order: the first slice with anti-calbindin (1:2000 - 
Abcam) polyclonal antibody, as positive control; the second slice with anti -gal (1:150 - 
Chemicon) polyclonal antibody; the third slice with anti-aldolase C (1:500 - PRIMM) 
polyclonal antibody as positive control. Staining was carried out with LSAB+System-HRP 
(DAKO); the signal was developed using diaminobenzidine (DAB) chromogen as substrate 
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(DAKO). The tissue sections were then lightly counterstained with Mayer‟s hematoxylin 
and cover-slipped.  
Different times were used for developing signal of endogenous aldolase C and calbindin in 
all transgenic mice (15 and 5 seconds, respectively) and of -gal in transgenic mice 
obtained with different constructs: 15–20 sec for pAldC-2500-LacZ (ctrl), 50 s for pAldC-
1464-LacZ, 15-20 for pAldC-1580-LacZ, 30 sec for pAldC-2336-LacZ.  
Images were acquired by NDP.view software (virtual microscopy by Hamamatsu). 
 
2.13 RNA extraction and Reverse Transcription Polymerase Chain Reaction (RT-
PCR)  
Total RNA was isolated from cultured PC12 cells using TRIzol® reagent (Invitrogen, life 
technologies) according to the manufacturer's protocol. 
Embryos from pAldC-2500-LacZ transgenic mice lines were obtained at developmental 
stages E13 and E15. pAldC-2500-LacZ transgenic mice were sacrificed at different 
developmental stages: P0 (newborn), P7, P14 and P42 (adult). Finally, pAldC-1580-LacZ,  
pAldC-1464-LacZ  and pAldC-2336-LacZ  transgenic mice were sacrificed only at adult 
stage. Total RNA was obtained from embryos head and from brain, cerebellum, heart, 
kidney and liver of pAldC-2500-LacZ transgenic mice at different developmental stages. 
Total RNA was also obtained from brain and cerebellum of pAldC-1580-LacZ, pAldC-
1464-LacZ and pAldC-2336-LacZ adult transgenic mice. Embryos head and the different 
organs were resuspended in Tryzol (Invitrogen, life technologies) and homogenized with 
an electric homogenizer. Successive steps have been performed according to the 
manufacturer‟s instructions. 
Total RNA was retro-transcribed into cDNA by using the commercial kit SuperScript III 
Reverse Transcriptase (Invitrogen). 12-18 bp oligo(dT) were used as primers annealing the 
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mRNA polyA tails. The retrotranscription reaction was performed using the ICycler PCR 
machine from BioRad and following these steps: 
 Denaturation and Annealing   60°C x 5‟ 
 Polymerization     50°C x 1h 
 Inactivation     70°C x 15‟ 
After DNase I treatment,  first-strand cDNA was synthesized from 1 µg total purified RNA 
from PC12 cells and transgenic mice tissues respectively. Retrotranscription was carried 
out using 1 l of 0.5 mg/ml oligo(dT) primers (Invitrogen) and 0.5 l of 25 mM dNTP for 
the first step. Then the reaction was stopped and samples were put on ice for 5 minutes to 
help the stabilization of single strand RNA molecules. Successively, 1 l of SuperScript III 
RT (200U/ ml), 4 l of 5X First-Strand Buffer [250 mM Tris-Hcl pH 8.3, 375 mM KCl, 15 
mM MgCl2] and 1 l of 0.1M DTT were added to perform the second and third step. 
Finally, cDNA samples were kept at 4°C.  
 
2.14 Real Time quantitative-PCR  
Total RNA was obtained from PC12 cells, embryos and different organs of pAldC-2500-
LacZ transgenic mice at different developmental stages and from brain and cerebellum of 
pAldC-1580-LacZ, pAldC-1464-LacZ and pAldC-2336-LacZ adult transgenic mice as 
described previously. 
Relative cDNA samples obtained by RT-PCR were analysed by Real Time quantitative-
PCR (RTqPCR). 
To analyze aldolase C messenger expression in PC12 cells untreated and treated with NGF, 
RTqPCR reactions were set up according to Liss et al. (90) and using: the housekeeping 
gene ABL, which has a constant copy number during neuronal differentiation, as 
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normalizer; GAP43 as differentiation marker; the aldolase C mRNA from untreated PC12 
cells, as calibrator. 
As concern pAldC-2500-LacZ transgenic mice, the aim was to analyse and compare 
expression pattern of endogenous aldolase C and transgenic LacZ messengers during brain 
development.  
RTqPCR reactions were set up according to Liss (90) and using two standards: the 
housekeeping gene 18S rRNA, which has a constant copy number in all developmental 
stages, as normalizer; the aldolase C and LacZ mRNA at developmental stages in which 
their expression is the lowest in the different tissues, as calibrators.  
As concern pAldC-1580-LacZ, pAldC-1464-LacZ and pAldC-2336-LacZ transgenic mice, 
LacZ messenger expression pattern was analysed and compared with that of pAldC-2500-
LacZ  transgenic mice only at adult stage. 
Even in this case the housekeeping gene 18S rRNA was used as normalization target; 
instead, LacZ messenger from pAldC-2500-LacZ adult transgenic mice was used as 
calibrator. 
Oligo4 software was used to design oligonucleotides as follows: 
ABL Fw: 5‟-GGTATGAAGGGAGGGTGTACCA-3‟ 
ABL Rev: 5‟-GTGAACTAACTCAGCCAGAGTGTTGA-3‟ 
GAP43 Fw: 5‟-CAGGTTGAAAAGAATGATGAGG-3‟ 
GAP43 Rev: 5‟-GCATCGGTAGTAGCAGAGCC-3‟ 
Ald C Fw: 5‟-TGCCCTGCGTCGTACTGTGC-3‟ 
Ald C Rev: 5‟-TGCAAGCCCGTTCATCTCTG-3‟ 
LacZ Fw: 5‟-ATGATTACGGATTCACTGGCCGTC-3‟ 
LacZ Rev: 5‟-TCGGCATAACCACCACGCTCATC-3‟  
18S rRNA Fw: 5‟-CATGGTGACCACGGGTGAC-3‟ 
18S rRNA Rev: 5‟-TTCCTTGGATGTGGTAGCCG-3‟ 
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The efficacy and specificity of these primers were tested by dilution experiments and 
melting curves. 
Real-time quantitative PCR was performed using an iQ5-iCycler Optical System (Bio-
Rad). IQ SYBR [100 mM KCL, 40 mM Tris-HCl pH8.4, 0.4 mM dNTPs, iTaq DNA 
polymerase 50U/ml, 6 mM MgCl2, SYBR Green I, 20 nM fluorescein, stabilizer] (Bio-
Rad) was used according to the manufacturer's instructions. Reactions were incubated  for 
10‟ at 95°C, followed by 40 cycles of 15” at 95°C and 1‟ at 60°C. Finally, a temperature 
gradient was applied starting at 55°C and increasing the temperature of 0,5°C every 10‟‟ 
up to 95°C. Fluorescence signals were measured during the elongation step. All reactions 
were performed in triplicate.  
The “ 2-∆∆Ct ” method of relative quantification was used as reported elsewhere (91). 
 
2.15 Site-directed Mutagenesis by PCR 
The mutant genes coding for chimeric AC and CA aldolases were generated via multiple 
site-directed mutagenesis using overlapping oligodeoxyribonucleotides that complement 
the high copy ATG vector pPB14 (92) expressing rabbit aldolase A and human C used as 
template, respectively.  
Primers used to amplify AC chimeric aldolase gene are: 
F1 (gene U): 5‟-ACGACCGAGCGCAGCGAGTCAGTGAG-3‟ 
R1-AC: 5‟-CTTCGCcATGCTCCCGGTCGACTCATCTG-3‟ 
F2-AC: 5‟-GAGTCGACCGGGAGCATgGCGAAGAGGCTGCAAcaGATCG 
GTAC-3‟ 
R2-AC:5‟-GGAAGAGGATGACGCCCCCGATGCActtGTTCACGCGGTCA-3‟ 
F3-AC: 5‟-GACCGCGTGAACaagTGCATCGGGGGCGT-3‟ 
R3-AC: 5‟-GCCCACAACAatGCCCTTGGACTTGATAACTTGCGGGAAGGG 
AacCCCATCGTCC-3‟ 
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F4-AC: 5‟-TATCAAGTCCAAGGGCatTGTTGTGGGCATCAAG -3‟ 
R4-AC: 5‟-GAGGGGGTGcGTTCCCCAATCTTCAG-3‟ 
F5-AC: 5‟-GCTGAAGATTGGGGAACgCACCCCCTCAGC-3‟ 
R5-AC: 5‟-CCTTCTTCCCACgCCAGGCgTTCAGAGCCGA-3‟ 
F6-AC:5‟-GCAGGCCTCGGCTCTGAAcGCCTGGcGTGGGAAGAAGGAG-3‟ 
R6-AC:5‟-GTTGGCCtcGGCCCGCTTCACGaACTCCTCcGTGGCAGCCTT-3‟ 
F7-AC: 5‟-GCCacGGAGGAGTtCGTGAAGCGGGCCgaGGCCAACAGCCT-3‟ 
R7-AC: 5‟-AGGCGTGGTTAGcGATGAAGAGGGACTgGgcGGCCGCGcCCC 
CGGCCT-3‟ 
F8-AC: 5‟-CCCTCTTCATCgCTAACCACGCCTACTA-3‟ 
R8 (Gene L): 5‟-GCTACTGCCGCCAGGCAAACTGTTTTATCAG-3‟ 
Primers used to amplify CA chimeric aldolase gene are: 
F1 (gene U): 5‟-ACGACCGAGCGCAGCGAGTCAGTGAG-3‟ 
R1-CA: 5‟-CAGCCGCTTGGCgATGCTGCCTACA-3‟ 
F2-CA: 5‟-CTGTAGGCAGCATcGCCAAGCGGCTGAGCtcAATTGGGG 
TGG-3‟ 
R2-CA: 5‟-GACGCCTCCAATGCACggTTTCACACGGTCA-3‟ 
F3-CA: 5‟-GCTGATGACCGTGTGAAAccGTGCATTGGAG-3‟ 
R3-CA: 5‟-GCCCACGACGccGCCCTTATCCTGGATGGTTCGGACGAA 
GGGAcgACCATTATCA-3‟ 
F4-CA: 5‟-CCAGGATAAGGGCggCGTCGTGGGCATC-3‟ 
R4-CA: 5‟-GCAGAGGGTGTAtGCTCACTGATTTTCA-3‟ 
F5-CA: 5‟-GCTGAAAATCAGTGAGCaTACACCCTC-3‟ 
R5-CA: 5‟-CCCGTTGCCCTCcCCAGGCtTTGAGTGCAGAGGCT-3‟ 
F6-CA: 5‟-CTGCACTCAAaGCCTGGgGAGGGCAACGGGACAATGCTGG 
GGCTGCCcaaGAGGAGTaCATCAAGCGGGCTctGGTGAATGGGC-3‟ 
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R6-CA: 5‟-CAGCCAAGCTTCAGTAGGCATGGTTGGaAATGTAGAGTGA 
CTcactTGCTGCTgCACCATCTTCT-3‟ 
Red nucleotides refer to the codon that has been changed from that of the wild-type 
aldolases A and C. Mutated nucleotides are shown in lower case. The resulting missense 
mutations and their consequent amino acid substitutions are shown in Table 1.  
The production of the two chimeric genes involved three steps (see schematic 
representation in Fig. 5 A and B):  
1) 8 and 6 different overlapping fragments were amplified for generating AC and CA 
chimera genes, respectively; 
2) the amplified fragments 1, 2 and 3 were fused togheter by PCR using F1 and R3 
primers for AC and CA genes; the fragments 4 and 5 were fused by using F4 and R5 for 
AC and CA genes; the fragments 6, 7 and 8 were fused by using F6 and R8 (only for 
chimeric gene AC); 
3) the fusion products 1-2-3, 4-5 and 6-7-8 were further fused togheter by using only 
F1-AC and R8-AC primers for amplifying the whole AC chimera gene; the fusion products 
1-2-3, 4-5 and 6 were fused togheter by using only F1-CA and R6-CA primers for 
amplifying the whole CA chimera gene. 
The amplification of each single fragment (first step) was performed using the recombinant 
DNA polymerase taq (Roche) by incubating samples at 95 °C for 1 minute followed by 35 
cycles of denaturation at 95 °C for 30 seconds, annealing at 50 °C for 30 seconds, and 
elongation at 72 °C for 1 minute. A final step was performed at 72°C for 10 minutes. The 
fusion fragments (second step) were amplified using the same protocol of single fragments 
except for the annealing temperature which ranged between 50°C and 60°C for the 
different fragments and for the elongation step of 2 minutes instead of 1. The final 
fragments (third step) were amplified by incubating samples at 95°C for 2 minutes, 
followed by 28 cycles of denaturation at 95 °C for 1 minute, annealing at 50-54 °C for 30 
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seconds, and elongation at 72 °C for 2 minutes. A final step was performed at 72°C for 10 
minutes. 
25 ng of pPBI vectors expressing wt rabbit A and human C aldolases were used as 
template for generating single fragments. For the second and third steps, 100fmol of single 
and fused fragments were used as template. 
The final mutant genes were screened by DNA sequence analysis at CEINGE 
(Biotecnologie Avanzate s.c.ar.l., Napoli, Italia). 
48 
 
 
Enzyme Primers Codon 
substitutions 
Residue 
number 
Aminoacid 
substitution 
AC chimera R1, F2 ATC__ATg 39 Ile_Met 
AC chimera F2 TCG__caG 45 Ser_Gln 
AC chimera R2, F3 CCC__aag 71 Pro_Lys 
AC chimera R3 CGT__gtT 91 Arg_Val 
AC chimera R3, F4 GGT__atT 102 Gly__Ile 
AC chimera R4, F5 CAC__CgC 156 His__Arg 
AC chimera R5, F6 AAG__AAc 311 Lys__Asn 
AC chimera R5, F6 GGT__cGT 314 Gly__Arg 
AC chimera R6, F7 CAG__acG 324 Gln__Thr 
AC chimera R6, F7 TAC__TtC 327 Tyr__Phe 
AC chimera R6, F7 CTG__gaG 332 Leu__Glu 
AC chimera R7 GCC__GgC 350 Ala__Gly 
AC chimera R7 AGC__gcC 353 Ser__Ala 
AC chimera R7 GAG__cAG 354 Glu__Gln 
AC chimera R7, F8 TCT__gCT 359 Ser__Ala 
CA chimera R1, F2 ATG__ATc 39 Met__Ile 
CA chimera F2 CAA__tcA 45 Gln__Ser 
CA chimera R2, F3 AAG__ccG 71 Lys__Pro 
CA chimera R3 GTT__cgT 91 Val__Arg 
CA chimera R3, F4 ATC__ ggC 102 Ile__Gly 
CA chimera R4, F5 CGT__ CaT 156 Arg__His 
CA chimera R5, F6 AAT __ AAa 311 Asn__Lys 
CA chimera R5, F6 CGA__gGA 314 Arg__Gly 
CA chimera F6 ACT__caa 324 Thr__Gln 
CA chimera F6 TTC__TaC 327 Phe__Tyr 
CA chimera F6 GAG__ctG 332 Glu__Leu 
CA chimera R6 GGA__GcA 350 Gly__Ala 
CA chimera R6 GCA__agt 353 Ala__Ser 
CA chimera R6 CAG__gAG 354 Gln__Glu 
CA chimera R6 GCC__tCC 359 Ala__Ser 
 
Table 1. Site directed mutagenesis. Primers, codon and aminoacid substitutions with 
relative residue number are indicated both for chimeric aldolase AC and CA. 
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Figure 5. Schematic representation of three steps of PCR-assisted multiple site-
directed mutagenesis performed to amplify AC (A) and CA (B) aldolase chimeric 
genes. Engineered ISRs, primers location and relative overlapping regions are shown both 
regarding AC and CA chimera genes. The three steps of PCR are also shown with a 
schematic overview. 
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2.16 Cloning and expression of chimeric aldolase A/C and C/A genes 
The final PCR fusion products coding for chimeric AC and CA aldolase genes were 
purified from agarose gel (Qiaquick gel extraction kit, Qiagen) and cloned in TOPO-TA 
cloning vector (Invitrogen). Further mutagenesis were performed in order to insert 
restriction enzymes sites for NdeI at 3‟ end of AC and CA gene and for XhoI at 5‟ end of 
CA gene, using relative AC- and CA-TOPO-TA constructs as template. The primers used 
for the mutagenesis are: 
Fw mut NdeI AC: 5‟-TCACACAGGAAACAGCATATGCCTCACTCCCATCCAGCG-3‟ 
Rv mut NdeI AC: 5‟-CGCTGGATGGGAGTGAGGCATATGCTGTTTCCTGTGTGA-3‟ 
Fw mut NdeI CA: 5‟- CACACAGGAAATAGCATATGTCACCTCACTCGTACCCAGC 
CC-3‟ 
Rv mut NdeI CA: 5‟-GGGCTGGGTACGAGTGAGGTGACATATGCTATTTCCTGTG 
TG-3‟ 
Fw mut XhoI AC: 5‟- CGCCCCCTCAACACTCGAGGCTCCAGCACCGG-3‟ 
Rv mut XhoI AC: 5‟- CCGGTGCTGGAGCCTCGAGTGTTGAGGGGGCG-3‟ 
These mutagenized genes were digested, purified (Qiaquick gel extraction kit, Qiagen) and 
cloned in the expression vector PET16b by using restriction enzymes NdeI (3‟) and XhoI 
(5‟) for AC aldolase gene and NdeI (3‟) and BamHI (5‟) for CA aldolase gene. PET16b 
expression vector carries the IPTG (indolyl-β-D-galactopyranoside) inducible T7 promoter 
at the 5‟ of the multiple cloning sites, and an His-Tag coding sequence (6 histidine 
residues) at the 3‟ end. Each step of cloning and mutagenesis was followed by sequencing 
(CEINGE Biotecnologie Avanzate s.c.ar.l., Napoli, Italia). The resulting N-terminal HIS-
tagged chimeric aldolase proteins were expressed in BL21 competent cells which express 
the T7 RNA polymerase. 
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2.17 Affinity chromatography and recombinant aldolases purification  
The HIS-tagged chimeric aldolases were purified through affinity chromatography using a 
Nickel resin (Ni-NTA Superflow, Qiagen) binding the HIS-tag of wt and chimeric 
proteins. Buffers containing 300 mM NaCl, 50 mM NaH2PO4 pH 8.0, 20% glycerol and 
increasing concentration of Imidazole were used to lysate the cells (20 mM Imidazole), 
wash the columns (50 mM Imidazole) and elute the samples (250 mM Imidazole 
competing with the proteins HIS-tag for the Nickel resin binding). 
The preparation and purification of chimeric proteins was performed as follows: 
 25 l from stabs of BL21 bacterial cells transformed with PET16b constructs 
containing wt and chimeric genes (PET16b-AldoAwt; PET16b-AldoCwt; PET16b-
AldoAC; PET16b-AldoCA) were inoculated in 5 ml LB (Luria Bertani) medium 
plus ampicillin and let grow O.N at 37°C;  
 Inocules were diluted 1:100 in 500 ml of LB medium plus ampicillin and let grow 
at 37°C until they reach an inducible 0,4-0,6 optical density (O.D.) measured at 600 
nm with the spectrophotometer (Cary 50 Bio, Varian);  
 BL21 cell cultures were induced by adding  IPTG to a final concentration of 1 mM; 
 After 3 hours, cell cultures growth was stopped and the O.D. units were measured 
with the spectrophotometer (1,5-2 O.D.); 
 BL21 cell coltures were centrifuged at 3.000 rpm for 30 minutes; 
 Pellets were put on ice, resuspended in 20 mM Imidazole Buffer, sonicated 30‟‟ for 
6 times and syringed 2 times;  
 Samples were centrifuged at 9.000 rpm for 45 minutes at + 4°C;  
 Supernatants were incubated with 450 l of NicKel resin (Promega) for 1 hour on a 
rotating platform at + 4°C; 
 Samples were loaded on columns; 
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 Columns were washed 2 times with 4 ml of 50 mM Imidazole buffer; 
 10 fractions were eluted with 225 l  of 250 mM Imidazole Buffer;  
 The concentration of each proteic fraction was determined with the 
spectrophotometer (Cary 50 Bio, Varian) by performing a Biorad assay and 5 l of 
each fraction was also loaded on a 10% acrylamide gel (SDS-PAGE) and checked 
through coomassie staining ; 
 The more concentrated fractions, generally the first 7 fractions, were pulled 
togheter and dialysed against TRIS 20 mM and Glycerol 50% O.N. at 4°C; 
 Concentration of dialysed proteins was quantified by spectrophotometer readings; 
 Purified proteins were aliquoted and kept at -20°C.  
 
2.18 Steady-state Kinetics 
Aldolase activity toward fructose-1,6-bisphosphate (FBP) was measured as described 
previously (93, 94). Briefly, a decrease in absorbance at 340 nm was measured from an 
assay coupled to -NADH oxidation by glycerol-3-phosphate dehydrogenase. The reaction 
was as follows: 
 
FBP
    ALDOLASE
  GAP + DAP 
GAP 
      TIM
   DAP 
2 DAP + 2 NADH + 2H
+         GDH
       2glycerol-1-phosphate + 2 NAD
+
 
 
Loss of NADH is proportional to conversion of DHAP to G3P, and the creation of DHAP 
is proportional to FBP cleavage (aldolase activity).  
Enzymes were diluted in 50 mM TRIS-HCl (pH 7.4), 10 mM EDTA, 20 g/ml glycerol-3-
phosphate dehydrogenase, 20 g/ml triosephosphate isomerase (Sigma), and 0.2 mM -
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NADH (Sigma). Assays were performed at 20°C and 30 °C in triplicate using a Cary 1E 
UV-vis spectrophotometer (Varian) in a final volume of 1 ml. Reactions were monitored 
every second for 5 minutes. For the AC chimera, the FBP concentration ranged from 10 
mM to 50 M with 3 g/ml enzyme. For the CA chimera the FBP concentration ranged 
from 3 mM to 10 M with 3 g/ml enzyme. For the wt A and C aldolases, the FBP 
concentration ranged from 2 mM to 10 M with 3 g/ml enzyme. Results were analysed 
by the Kaleidagraph programme. 
 
2.19 Preparation of construct for aldolase C - conditional knockout 
The EMBL (European Molecular Biology Laboratory) of Monterotondo (Rome) provided 
us the construct to produce a conditional knockout mouse for aldolase C gene. 
The construct is 11.555 bp long. It shows, from the origin (5‟) to the end (3‟), the 
ampicillin resistance cassette, the aldolase C gene from the 3‟ end to the 5‟ end, interrupted  
between the VII and the VI exon where the neomycin (neo) cassette is inserted. The neo 
cassette is flanked by FRT sequences (target of the FLP recombinase) and two loxP 
sequences (target of CRE recombinase) are present, one between the VII exon and the first 
FRT sequence and the other between the third and second exon of aldolase C gene. 
The strategy includes a first recombination event mediated by the FLP recombinase, in 
order to excide the neo cassette, and a second recombination mediated by CRE 
recombinase exciding the central part of the gene, from exon II to VI.  
 
2.20 From electroporation of ES cells to microinjection into mouse blastocysts: 
chimera mouse 
The steps going from the electroporation of ES cells to the final production of chimeric 
mice were provided from EMBL as well as the production of the construct. 
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BRUCE 4 cells deriving from C57black/6 mice were electroporated, 500 clones were 
picked and the first 200 were screened by Southern Blot. 8 clones were found to be 
positive (4% recombination). Positive clones were expanded and reconfirmed by Southern 
Blot. Three of these positive clones were microinjected into the blastocysts of C57bl/6 wt 
sacrificed pregnant mice and the blastocysts were reimplanted into the utherus of C57bl/6 
wt pseudopregnant mice. A total of 4 chimeric mice (1 female and 3 males) were finally 
provided us from EMBL.  
 
2.21 Screening of  F1 generation by PCR 
4 chimeric mice provided us from EMBL were crossed at CEINGE animal house with wt 
mice. About 375 pups were obtained (F1 generation) and screened for germline 
transmission by PCR. 
DNA was extracted from the tail of the pups using the following protocol: 
 750 l of lysis buffer ( Tris HCl pH 8.5 100 mM, EDTA 5 mM, NaCl 200 mM and 
SDS 0,2 %) and 40 l of Proteinase K (stock 10mg/ml) were added to the tails and 
incubated O.N. at 55°C on a platform shaker; 
 The day after, samples were vortexed 5 minutes, added with 250 l of 6 M NaCl 
and vortexed again for 10 minutes; 
 Samples were centrifuged at 14.000 rpm, 10 minutes at 4°C; 
 500 l of isopropanol were added to the supernatant and samples were vortexed for 
2 minutes; 
 Samples were centrifuged at 14.000 rpm, 5 minutes at 4°C; 
 Pellets were resuspended in 1 ml of 70% cold ethanol and centrifuged at 14.000 
rpm for 3 minutes at 4°C; 
 Supernatants were taken off and samples were centrifuged again 20 seconds; 
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 Supernatant residues were gently removed and pellets were dryed at room 
temperature for 15 minutes; 
 100-200 l of TE were added to the pellets and mixed at 4°C until the DNA was 
completely dissolved. 
50 ng of DNA from F1 mice were amplified by PCR using the following primers and 
protocol: 
Fw: 5‟- GGTTAGGAGAGGAAGTAGAAGG-3‟ 
Rev: 5‟- CCCAATGCACTTTTTCACAC-3‟ 
1 step: 
 Denaturation   94°C x 2‟ 
35 cycles of:  
 Denaturation   94° C x 30‟‟ 
 Annealing   55°C x 30‟‟  
 Polymerization  72°C x 30‟‟  
A final step of 
 Extension   72°C x 2‟. 
Forward and reverse primers were located at the 5‟ and 3‟ of the first loxP sequence, in the 
second intron. The amplified product from F1 mice positive to germline transmission is a 
DNA doublet (386 and 424 bp) relative to the wt and the floxed allele. In case of negative 
germline transmission, the primers would map only on the wt gene and the amplified 
product would be a 386 bp DNA singlet.  DNA from chimeric mice was used as positive 
control. 
56 
 
3.  RESULTS 
 
3.1 Transcriptional regulation of human aldolase C gene during NGF-induced 
neuronal differentiation in PC12 cells 
 
3.1.1 Analysis of aldolase C messenger expression during NGF-induced neuronal 
differentiation 
We previously demonstrated that human aldolase C mRNA expression is positively 
regulated by 8 Br-cAMP treatment in PC12 cells (44). Here, we analysed aldolase C 
mRNA expression in PC12 cells induced to neuronal differentiation with NGF.  
Aldolase C mRNA expression was measured in PC12 cells untreated and treated with 100 
ng/ml NGF for different times (30 min, 4 h, 1, 3, 7 and 14 days) by Real Time quantitative 
PCR, as described in the paragraph 2.12 of Materials and Methods. At the same time, we 
evaluated the effect of neuronal differentiation mediated by cell-growth inhibition in PC12 
cells on aldolase C mRNA expression. 
We used GAP43 mRNA as marker for neuronal differentiation which expression is known 
to be positively modulated during neuronal differentiation induced by NGF treatment.  
In fact, GAP43 mRNA expression is barely detectable in undifferentiated PC12 cells (ctrl); 
significant increase  mRNA expression is evident from 30 minutes  NGF treatment with a 
40-fold maximal expression found after 14 days of treatment (Fig. 6A, 30 min, 4h, 1, 3, 7 
and 14 days, blue bars).  
In untreated cells, GAP43 mRNA expression was significantly up-regulated from 7 days 
after plating, when cells reached confluence, and no additional increase was evidenced 
after 14 days of culture compared with 7 days (Fig. 6A, 7 days vs 14 days, green bars). 
This observation supports the hypothesis that GAP43 mRNA is specifically up-regulated 
57 
 
by NGF, and that cell growth arrest had minimal role in the modulation of GAP43 
expression (maximum 8-fold to respect ctrl, Fig. 6A, green bars).  
Similarly to GAP43, a slight positive modulation of aldolase C mRNA expression is 
detectable 7 days after plating (about 3-fold increase compared to ctrl); futher increase is 
present after 14 days, about 8-fold (Fig. 6B, green bars). This increase parallels GAP43 
mRNA increase (Fig.6 A-B, compare green bars) suggesting that neuronal differentiation 
induced by cell-growth inhibition is also able to induce a weak up-regulation of aldolase C 
mRNA expression (Fig. 6A green bars).  
In NGF treated cells, an early increase (about 2-fold) of aldolase C mRNA expression is 
already evident after 30 minutes of treatment, compared to ctrl; further significant 
increases are evident after 4 hours and until 7 days of treatment; maximal increase, about 
10-fold, is evident after 14 days of treatment (Fig. 6B, blue bars).  
Aldolase C mRNA expression parallels GAP43 mRNA expression starting from 30 
minutes of treatment and reaching maximal expression levels after 14 days of treatment, 
even if aldolase C levels are lower than those of GAP43 (Fig. 6B, blue bars). 
These results support the hypothesis that aldolase C mRNA expression is specifically up-
regulated during neuronal differentiation mediated by NGF. Moreover our results indicated  
that aldolase C mRNA up-regulation is mediated by NGF treatment during the first 3 days, 
and from 7 to 14 days of treatment an additive effect, due to cell-growth inhibition, 
positively modulates aldolase C mRNA expression.  
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Figure 6.  
Real Time quantitative PCR of GAP43 and aldolase C. 
Relative abundance of GAP43 (A) and aldolase C (B) mRNA were determined by RT-
qPCR, using c-ABL mRNA as internal standard. PC12 cells were treated for 30 min, 4 h, 
1, 3, 7 and 14 days with 100 ng/ml of NGF. Arbitrary expression value 1 was assigned to 
untreated PC12 cells (ctrl). Relative aldolase C mRNA increase was calculated as 2CT. 
Data shown represent the mean +/- SD of three independent experiments that gave same 
results. 
. 
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3.1.2 Identification of  human aldolase C gene promoter region responsive to NGF 
Two regions in the promoter of human aldolase C gene have been identified and 
characterized so far. These regions are involved in the complete and correct transcription 
of the gene in human cell lines and in the adult mouse brain, Fig. 1A (40). In the distal 
promoter region of the human aldolase C gene we identified the element D (-203/-196 bp, 
Fig. 1A) that binds the transcriptional activator NGFI-B and mediates cAMP up-regulation 
of the aldolase C mRNA in PC12 cells. In order to assess whether increased expression of 
the messenger, detectable after 3 days of NGF treatment, was due to a transcriptional 
event, and to identify cis-element(s) responsive to NGF in the promoter of the gene, we 
performed transient transfection experiments in PC12 cells treated with NGF. Six CAT-
reporter plasmids containing the complete promoter region (from -1190 to +20bp), -1190-
CAT, or deleted regions of the promoter: -420-CAT, -260-CAT, -260*-CAT, -208-
CAT and -164-CAT, have been used. -164-CAT construct, containing the proximal 
promoter region (-164/+20 bp)  shows minimal transcriptional activity, about 4% (Fig. 7, 
green bar) and no significant variation in CAT-activity was observed after NGF treatment 
(100 ng/ml) for 3 days (Fig. 7, blue bar). This demonstrates that, similarly to that 
previously observed in SKNBE and in PC12 cells treated with cAMP, the proximal 
promoter region (-164 to +20 bp) of the human aldolase C gene is required only for 
minimal transcriptional activity (40). The region from -208 to -260 bp is required for 
transcriptional activation of the gene, as evidenced by significant increase, about 3-fold of 
CAT activity of -208-CAT, and about 4-fold of CAT activity of the -260- and -260*-
CAT constructs with respect to -164-CAT construct (Fig. 7, green bars).  Treatment with 
NGF for 3 days produced a further increase, about 5-fold, in the CAT activity of -208-
CAT compared to -164-CAT construct (Fig. 7, blue bar) and of about 8-fold in -260- 
and -260*-CAT constructs with respect to -164-CAT (Fig. 7, blue bars). This result 
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supports the hypothesis that increase in aldolase C mRNA expression found after 3 days of 
NGF treatment was due to a transcriptional activation mechanism and indicates the region 
from -208 to -260 bp in the distal promoter as responsive. Furthermore, since the binding 
site for element D in the -260*-CAT construct was destroyed, this indicates that further 
cis-elements different from element D, mediate the up-regulation of human aldolase C 
gene transcription during NGF treatment. Our results also evidenced in the distal region of 
the human aldolase C gene two additional segments involved in the transcriptional 
regulation: the segment from -260 to -420 bp and the segment from -420 to -1190 bp. CAT 
activity of  -420- and -1190-CAT constructs were similar to -164-CAT construct 
activity and was reduced with respect to -260-CAT construct (Fig. 7, green bars). This 
suggests that transcriptional repressor(s) bind the region from -260- to -1190 bp. 
Interestingly, NGF treatment produces about 2-fold increase in the -420-CAT and -
1190-CAT constructs activity (Fig. 7, blue bars), suggesting that NGF mediates removal of 
negative transcriptional regulators from distal region of aldolase C promoter region.  
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Figure 7.  
Scheme of CAT-constructs and relative CAT activity. 
PC12 cells were transiently co-transfected with pRL-LUC plasmid as internal standard and 
with different aldolase C promoter-CAT constructs, containing serial deletions of the 
promoter region or site-directed mutation of the NGFI-B trascription factor (260*-CAT) 
binding site. Aldolase C-CAT constructs are shown on the left. pEMBL-CAT and CMV-
CAT are used as negative and positive controls, respectively. Cells were untreated (green 
bars) and treated with 100 ng/ml NGF for 3 days (blue bars). The data represent the mean 
+/- SD from three independent experiments performed in duplicate. Relative CAT activity 
is reported as the percentage to respect to CMV-CAT activity (taken as 100%). 
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3.1.3 Identification of a transcriptional factor binding in the distal  promoter region 
of human aldolase C gene responsive to NGF 
In order to evidentiate binding site(s) for transcriptional activators in the distal promoter 
fragment (-164/-260 bp) of human aldolase C gene, responsive to NGF treatment, we  
performed electromobility shift assays using nuclear extracts from PC12 cells untreated 
and 3 days-treated with NGF and BRDL1 oligonucleotide (-245/-194 bp, Fig. 8A) as 
probe. In untreated cells 4 shifted complex are detectable: C1, C2, X and C3 (Fig. 8B, lane 
2). These complexes are specifically competed by a 100 X molar excess of the same cold 
oligonucleotide BRDL1 (Fig. 8B, lane 3). When a 100 X molar excess of Sp1 aspecific 
oligonucleotide (Fig. 8A) is used, the binding of the 4 complexes does not disappear, thus 
confirming the specificity of this binding (Fig. 8B, lane 6).  C1, C2 and C3 complexes are 
specifically competed when a 100 X molar excess of L1 oligonucleotide (-211/-186 bp, 
Fig. 8A), containing the element D, and of 21-OH oligonucleotide (Fig. 8A), containing 
the binding site for NGF-IB in the 21-OH murine gene promoter, are used (Fig. 8B, lanes 
4, 5, 9, 10). These results suggest that complexes C1, C2 and C3 are represented by NGF-
IB and evidenced another specific complex that we called complex X, not due to NGFI-B 
binding. Furthermore the intensity of the complex X increased after the NGF treatment and 
two additional complexes appeared, C4 and C5 (Fig. 8B, lane 7). A 100 X molar excess of 
L1 and 21-OH oligonucleotides specifically competed the binding of C4 and C5 complexes 
suggesting that this could be due to  two different NGF-IB isoforms. 
In order to look for the identity of the complex X we used the TRANSFAC® database and 
the bioinformatic program EMBOSS TFSCAN. Two putative binding sites were found in 
the region spanning from -245 to -194 bp: the first was the target of the “Upstream 
stimulatory factor I” (USF1) transcriptional factor and the second was the target of the 
“Nuclear factor –I” (NF-I). A 35 bp oligonucleotide (BRD) spanning from -245 to -211 bp 
in the human aldolase C gene promoter (Fig. 8A) was used as probe in EMSA experiments 
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conducted with nuclear extracts from PC12 cells untreated and 3 days-treated with NGF. A 
retarded complex X is evidenced using nuclear extracts from untreated and 3 days NGF-
treated PC12 cells and oligonucleotide BRD as probe (Fig. 8C, lanes 2 and 7). The 
complex X disappeared when a 100 X molar excess of the same (BRD) unlabelled 
oligonucleotide (Fig. 8C, lanes 3 and 8) or 100 X molar excess of oligonucleotide Cons 
USF1, which contains the consensus sequence for USF1 (Fig. 8A), were added to the 
mixture (Fig. 8C, lanes 4 and 9). Retarded complex X didn‟t disappear when a 100 X 
molar excess of oligonucleotide Cons NF-I, which contains the consensus sequence for 
NF-I (Fig. 8A), or 100 X oligonucleotide L1, which contains the promoter sequence of 
human aldolase C gene spanning from -211 to -186bp (Fig. 8A), were added as aspecific 
competitors (Fig. 8C, lanes 6 and 11). Furthermore, a slight increase in retarded complex 
X, is evident after PC12 cells treatment with NGF for 3 days (Fig. 8C, lanes 7-11), that is 
in line with the CAT-activity increase of -260CAT plasmid after 3 days of NGF treatment 
(Fig. 7).  
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Figure 8. (A) Oligonucleotide  sequences of probes and competitors. (B) EMSA of -
245/-194 BRDL1 fragment in the promoter of human aldolase C gene. The 32P-
labelled BRDL1 probe was incubated in the absence (lane 1) or presence of 4 g nuclear 
extracts from untreated PC12 cells  (lanes 2-6) and 3-days NGF-treated cells (lanes 7-10). 
For competition experiments, a 100-fold molar excess of the unlabelled BRDL1 (lanes 3 
and 8), L1 (lanes 4 and 9), 21-OH (lanes 5 and 10) and Cons Sp1 (lanes 6) oligonucleotides 
were added to the binding reaction. (C) EMSA of -245/-211 BRD fragment in the 
promoter of human aldolase C gene. The 32P-labelled BRD probe was incubated in the 
absence (lane 1) or presence of 4 g nuclear extracts from untreated PC12 cells  (lanes 2-6) 
and 3-days NGF-treated cells (lanes 7-11). For competition experiments a 100-fold molar 
excess of the unlabelled BRD (lanes 3 and 8), Cons USF1 (lanes 4 and 9), Cons NF1 (lanes 
5 and 10) and L1 (lanes 6 and 11) oligonucleotides were added to the binding reaction.  
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3.1.4 Identification of USF1 as transcriptional factor binding to the distal region of 
human aldolase C gene promoter responsive to NGF treatment by chromatin 
immunoprecipitation (CHIP) assay 
To confirm the specificity of USF1 transcriptional factor binding to the element E (-245/-
211 bp) in the aldolase C gene promoter, a supershift experiment was conducted using 
specific anti-USF1 antibodies. Nuclear extracts from PC12 cells untreated (Fig. 9A, lanes 
2-9) and NGF 100 ng/ml treated for 3-days (Fig. 9A, lanes 10-15) were challenged with 
BRD oligonucleotide as probe. The specific complex X (Fig. 9A, lane 2) disappeared in 
presence of increasing amounts of anti-USF1 antibody both in untreated (Fig. 9A, lanes 6-
8) and in cells treated with NGF (Fig. 9A, lanes 12-14). Complex X remains evident when 
an aspecific antibody “Ab-asp ” was added to the binding mix (Fig. 9A, lanes 9 and 15).  
To validate the results obtained in vitro by EMSA, we tested whether USF1 binds the 
element E (-245/-211 bp) in the distal promoter region of human aldolase C gene, in vivo, 
by ChIP assay. The chromatin was cross-linked, sheared and immunoprecipited with anti-
USF1 antibody or using an aspecific antibody. The immunoprecipitated DNA fragments 
were PCR-amplified with primers called -319F and -201R (as described in Materials and 
Methods, Fig. 9B). A 100 bp amplicon, containing the -238/-233 E-box (Fig. 9B), was 
detected from the “input DNA” and from DNA fraction that was immunoprecipitated with 
anti-USF1 antibody (Fig. 9C, lanes 1 and 4); no amplicon was detected from DNA fraction 
immunoprecipitated with aspecific antibody (Fig. 9C, lane 3) or when no-antibody was 
added to the mixture (Fig. 9C, lane 2) . These results indicate that endogenous USF1 in 
PC12 cells binds the -238/-233 E-box in the distal promoter region of human aldolase C 
gene in vivo. 
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Figure 9. 
(A) EMSA of -245/-211 BRD fragment in the promoter of human aldolase C gene. 
4 g of nuclear extracts from untreated (Fig. 4A, lanes 2-9) and 3-days NGF-treated (Fig. 
4A, lanes 10-15) PC12 cells were incubated with increased amounts of polyclonal anti-
USF1 antibody (Fig. 4A, lanes 6-8, 12-14) using the 32P-labelled BRD probe described 
above. A 100-fold molar excess of the unlabelled probe was added to lanes 3 and 11. L1 
oligonucleotide was added as non-specific competitor to lane 5 and a non-specific antibody 
(Ab-asp) was added to lanes 9 and 15. (B) Schematic representation of a fragment of 
human aldolase C gene promoter. The location of primers -319F and -201R (arrows) 
used to amplify the Input DNA containing  the E-box are shown. (C) Chromatin 
immunoprecipitation analysis of USF1 binding to the aldolase C promoter in vivo. 
Soluble chromatin from SKNBE cells was immunoprecipitated using the USF1 antibody 
(ab-USF1) or incubated with normal rabbit serum (PI-IgG) or no antibody (No-ab) as 
negative control. The total extracted DNA (Input) prior to immunoprecipitation and the 
immunoprecipitated samples (anti-USF1, PI-IgG, no antibody) were PCR-amplified using 
primers specific to the –319/-201 fragment. 
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 3.1.5 Functional analysis of USF1 binding to element E in distal region of human 
aldolase C gene promoter 
To confirm that USF1 acts as a transcriptional activator of human aldolase C gene we 
prepared two constructs, p1E-TK-CAT and p3E-TK-CAT, containing one and three 
concatenated elements E, respectively, inserted upstream TK promoter and CAT reporter 
gene in the pTK-CAT plasmid (Fig. 10A). We used these constructs to perform transient 
transfection experiments in PC12 cells. Relative CAT activity was measured and compared 
to the activity of the empty pTK-CAT plasmid.  
One element E inserted before TK promoter in the p1E-TK-CAT plasmid accounted for 
about 5% of relative CAT activity compared with empty vector (p0E-TK-CAT) in 
untreated PC12 cells after 3 days from plating (Fig. 10B, green bars); this activity was 3-
fold increased when p3E-TK-CAT plasmid was used (Fig. 10B, green bar), suggesting that 
endogenous USF1 acts as a transcriptional activator in PC12 cells. p1E-TK-CAT plasmid 
activity was increased of 2,5-fold after 3 days of NGF treatment with respect to p0E-TK-
CAT activity in treated cells (Fig. 10B, blue bars). As could be expected p3E-TK-CAT 
plasmid activity was increased of about 5-fold after NGF treatment compared to p0E-TK-
CAT activity in treated cells (Fig. 10B, blue bars). 
These results strongly validate results obtained in vitro from transient transfection 
experiments in PC12 cells. Particularly, we suggest that the 2,5-fold increase in 
transcriptional activation of the construct -260-CAT after NGF treatment (Fig. 7) is 
closely related to USF1 binding to element E in the promoter region of human aldolase C 
gene.  
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Figure 10. (A) Scheme of p1E-TK-CAT and p3E-TK-CAT constructs. A schematic 
representation of the two constructs used for transient transfections of PC12 cells is shown. 
The sequence of element E is also reported. (B) Relative CAT activity of p1E-TK-CAT 
and p3E-TK-CAT constructs. PC12 cells were transfected with the p1E-TK-CAT or the 
p3E-TK-CAT reporter plasmid, containing one and three tandem copies of Element E, 
respectively, located upstream TK promoter and CAT reporter gene. pTK-CAT plasmid, 
not containing the Element E, was used as negative control. Cells were untreated (green 
bars) and treated (blue bars) with 100 ng/ml NGF for 3 days. pRL-LUC plasmid was co-
transfected as internal standard to normalize for differences in the transfection efficiency. 
The data represent the mean +/- SD from three independent experiments performed in 
duplicate. Relative CAT activity is reported as the percentage to respect CMV-CAT 
activity (taken as 100%). 
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3.1.6 Subcellular localization of USF1 in PC12 cells treated with NGF 
In order to assess if NGF treatment induces nuclear translocation of USF1 inducing its 
binding to element E in the promoter region of human aldolase C gene, we performed 
immunofluorescence experiments on PC12 cells untreated and treated for 3 days with 
NGF. We used anti-USF1 as primary antibody and the anti-Rabbit, FITC Conjugate, as 
secondary antibody. Cells were treated with DAPI solution for the nucleus staining.  
Results obtained pointed out that USF1 in untreated cells was localized in the cytosol (Fig. 
11, panel a) and after 3 days of NGF treatment it almost completely translocated into the 
nucleus (Fig. 11, panel b). 
Western blot analysis confirmed decreased levels of USF1 in cytosolic extracts from PC12 
cells after NGF treatment  for 3 days (Fig. 12A, lane 2) compared with untreated cells (Fig. 
12A, lane 1). Moreover, after 3 days of NGF treatment, more abundant levels of USF1 and 
its phosphorylated forms are present in nuclear extracts of PC12 cells (Fig. 12A, lane 4) 
with respect to untreated  cells (Fig. 12A, lane 3) and compared with cytosolic extracts 
(Fig. 12A, lanes 1, 2). 
Further EMSA experiments were performed in order to verify if USF1 phosphorylation 
mediates its binding to element E in the human aldolase C gene promoter. BRD labelled 
probe was incubated with nuclear (Fig. 12B, lanes 2-8, 16-18) and cytosolic (Fig. 12B, 
lanes 9-15) extracts from PC12 cells untreated (Fig. 12B, lanes 2, 9) and treated with NGF 
for 30 min, 4h, 1 day (Fig. 12B, lanes 3-5, 10-12) and 3 days (Fig. 12B, lanes 6-8, 13-18). 
100 X molar excess of the BRD (Fig. 12B lanes 8, 15) and L1 unlabelled oligonucleotides 
(Fig. 12B, lanes 7, 14) were used as self and non self competitors, respectively. 1 and 2,5 
units of CIP (Fig. 12B lanes 16, 17) and 2,5 units of CIP(in) (Fig. 12B, lane 18) were 
incubated with nuclear extracts from PC12 treated with NGF for 3 days. 
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Results obtained support the hypothesis that in cytosolic extracts USF1 is 
unphosphorylated (see Fig. 12A, lanes 1, 2) and hence unable to bind DNA (Fig. 12B, 
lanes 9-15).  Treatment with NGF induced USF1 phosphorylation and nuclear 
translocation  thus determining an increased binding to element E  (Fig. 12A, lane 4). 
Finally, the treatment with increasing amounts of phosphatase added to the mixture, 
induced a decrease of USF1 binding (Fig. 12B, lanes 16, 17), which was restored by 
inactivating the phosphatase (Fig. 12B, lane 18) . 
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Figure 11. Immunofluorescence analysis of PC12 cells and USF1 subcellular 
compartimentalization. PC12 cells untreated (a) and 100 ng/ml NGF treated for 3 days 
(b) were analyzed by immunofluorescence experiments. Protein expression was detected 
using a primary anti-USF1 specific polyclonal antibody and revealed using a secondary 
fluoresceinated antibody (anti-FITC) (USF1 a and b). Nuclei were stained with DAPI 
(Dapi a and b). Green and blue images were merged ( Merge a and b). 
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Figure 12. (A)  Western blot. Cytosolic (lanes 1-2) and nuclear (lanes 3-4) protein 
extracts (50 g) obtained from PC12 cells untreated  (lane 1 and 3) and 100 ng/ml NGF 
treated for 3 days (lanes 2 and 4) were analysed by SDS-PAGE. Polyclonal anti-USF1 
antibody was used to reveal USF1 and phosphorylated USF1 forms (pUSF1). As control, 
the anti--tubulin (-Tub) and the anti-cyclin A (Cyclin A) antibodies were used for 
cytosolic and nuclear extracts respectively. (B)  EMSA of -245/-211 BRD fragment in the 
promoter of human aldolase C gene. The 32P-labelled BRD probe was incubated in the absence 
(lane 1) or presence of nuclear extracts from untreated PC12 cells (lane 2) and treated with NGF 
for 30‟, 4h, 1 day (lanes 3-5) and for 3 days (lanes 6-8). BRD probe was also incubated with 
cytosolic extracts from untreated PC12 cells (lane 9) and treated with NGF for 30‟, 4h, 1 day (lanes 
10-12) and for 3-days (lanes 13-15). For competition experiments 100-fold molar excess of the 
unlabelled probe (lane 8, 15) or non-specific competitor (L1, lanes 7, 14) were added to the binding 
reaction. 1 and 2,5 units of CIP (lanes 16, 17) and 2,5 units of CIP(in) (lane 18) were incubated 
with nuclear extracts from PC12 treated with NGF for 3 days. 
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3.2 Transcriptional regulation of human aldolase C gene during development in 
transgenic mice 
 
3.2.1 Expression analysis of endogenous aldolase C and LacZ transgene messengers in 
pAldC-2500-LacZ transgenic mice during development 
As described in the introduction, we previously demonstrated that the construct pAldC-
2500-LacZ, containing the complete promoter region so far described (1200 bp) of human 
aldolase C gene up to the methionine in the second exon (1300 bp) fused to the reporter 
gene LacZ, directs brain-specific expression of the transgene in adult mice, with a stripe-
like distribution in the Purkinje cell layer of the cerebellum.  
During my PhD I contributed to the analysis of endogenous and hybrid aldolase C mRNAs 
expression in the brain and other organs of pAldC-2500-LacZ transgenic mice at different 
developmental stages in order to understand if this construct was able to drive brain-
specific LacZ expression also during development. 
Embryos from pAldC-2500-LacZ transgenic mice line were obtained at developmental 
stages E13 and E15. Mice from pAldC-2500-LacZ transgenic mice line were sacrificed at 
different developmental stages: P0 (newborn), P7, P14 and P42 (adult). We obtained total 
RNA from embryos body, head and liver at developmental stages E13 and E15; total RNA 
was also obtained from brain, cerebellum, heart, kidney and liver of transgenic mice at 
developmental stages P0 (newborn), P7, P14 and P42 (adult). Total RNA was reverse 
transcribed into cDNA to then perform RT-qPCR experiments as described in Materials 
and Methods. 
In liver, kidney and heart, both aldolase C endogenous and AldC/LacZ hybrid messengers 
are barely detectable in the earlier developmental stages and absent in adult stages (Fig. 
13). 
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Endogenous aldolase C mRNA starts to be detectable at E15 stage, then, in the brain, is 
abundant at birth (PO) and reaches maximal expression levels in the adult stage (P42) (Fig. 
14, blue bars); the AldC-LacZ hybrid messenger appears with a slight delay to respect to 
the endogenous messenger (PO instead of E15) and is expressed at lower extent to respect 
to the endogenous mRNA in developmental brain (from P0 to P14) (Fig. 14, yellow bars). 
However, its expression pattern follows the endogenous aldolase C mRNA expression 
pattern and the difference between endogenous and hybrid mRNAs levels becomes even 
lower in the adult stage (Fig. 14, green bars, P42).  
In the cerebellum, the hybrid messenger expression pattern (Fig. 15, yellow bars) is similar to 
that of the endogenous (Fig. 15, blue bars) even if it is postponed in time. 
These results suggest that the human aldolase C promoter, present in the construct pAldC-
2500-LacZ, contains all the elements necessary to direct brain-specific expression of the 
LacZ reporter gene in the adult mice brain. Lower levels of hybrid messenger in the 
developing brain also suggest that pAldC-2500-LacZ construct lacks some enhancer 
elements. Further experiments are in progress to verify these data and to obtain a larger 
construct containing the putative enhancer elements up to the 2500 bp fragment of human 
aldolase C promoter. 
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Figure 13. RT-qPCR on cDNA from heart, kidney and liver of pAldC-2500-LacZ 
transgenic mice during development. Endogenous aldolase C (blu bars) and LacZ (yellow 
bars) mRNA expression levels are shown. Data are presented as the means ± standard 
deviation of three separate experiments.  
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Figure 14. RT-qPCR on cDNA from brain of pAldC-2500-LacZ transgenic mice during 
development. Endogenous aldolase C (blu bars) and LacZ (yellow bars) mRNA expression 
levels are shown. Green bars represent the ratio between AldC and LacZ Ct values. Data are 
presented as the means ± standard deviation of three separate experiments.  
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Figure 15. RT-qPCR on cDNA from cerebellum of pAldC-2500-LacZ transgenic mice 
during development. Endogenous aldolase C (blu bars) and LacZ (yellow bars) mRNA 
expression levels are shown. Green bars represent the ratio between AldC and LacZ  Ct 
values. Data are presented as the means ± standard deviation of three separate experiments.  
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3.2.2 Identification of human aldolase C gene promoter region(s) regulating -
galactosidase activity in restricted areas  of adult transgenic mice CNS   
To further investigate the promoter regions of the human aldolase C gene involved in its 
brain-specific and compartment-limited expression, we produced new transgenic mice 
lines using three different constructs (Fig. 16): 
 construct pAldC-1464-LacZ, which contains only the proximal promoter region 
(164 bp); 
 construct pAldC-1580-LacZ, which contains the proximal region plus part of the 
distal region including the element E (280 bp); 
 construct  pAldC-2336-LacZ, which contains only the distal region (1036 bp) 
without the proximal promoter region. 
The  deleted regions (164 bp, 280 bp, 1036 bp) of human aldolase C promoter in all three 
constructs were cloned up to a 1300 bp fragment containing the first exon and the first 
intron up to the methionine in the second exon fused in frame with the reporter gene LacZ 
(Fig. 16): 
At least three different transgenic mice lines for each construct were stabilized and 
analysed by -galactosidase (-gal) assay: 
 construct pAldC-1464-LacZ, lines H5, H62, H69; 
 construct pAldC-1580-LacZ, lines I36, I37, I40; 
 construct  pAldC-2336-LacZ, lines N8, N10, N22 
Transgenic mice bodies were dissected from the brains and both were analysed by -gal 
assays: no -gal activity was found in the bodies of all transgenic mice lines (data not 
shown). Brains from transgenic mice lines obtained with the same construct showed 
similar -galactosidase expression patterns. As expected, among the three different lines, 
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-gal activity was found in different brain areas and with different expression levels (Fig. 
17, 18, 19). 
-gal assays were performed on whole mount brain from transgenic mice lines H, I and N, 
and in some cases on brain sagittal sections. 
-gal activity was found to be very low in the brain of line H transgenic mice, specifically, 
in the hippocampus (h), amygdala (amg) and olfactory bulbs areas (ob) (Fig. 17, panels A, 
B, C). No -gal activity was revealed in the cerebellum.  
Transgenic mice from line I showed very strong -gal activity in different areas of the 
brain like olfactory bulbs (ob), hippocampus (h), amygdala (amg), medulla (m) and 
cerebellum (cb) (Fig. 18A).  Panels B and C of figure 18 show higher magnifications of 
cerebellum, with a clearly detectable striped-distribution of -gal, and hippocampus with 
the dentate gyrus (DG), CA1 and CA3 neurons strongly expressing -gal. 
Finally, transgenic mice from line N showed a scattered -gal expression in cerebral cortex 
(cc), olfactory bulbs (ob), hippocampus (h) and midbrain (mb) with a highest staining in 
the Purkinje cell layer of the cerebellum (cb) (Fig. 19, panels A and B). 
-gal expression was successively analysed through immunohistochemistry in order to 
validate these results also at a single-cell level. 
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Figure 16. 
Schematic representation of constructs pAldC-1464-LacZ, pAldC-1580-LacZ and 
pAldC-2336-LacZ compared to pAldC-2500-LacZ.  
Each construct contains different deleted regions of human aldolase C gene promoter (blue 
bars represent the distal region and red bars the proximal region) plus a 1300 bp fragment 
containing the first exon, the first intron and the second exon up to the methionine (green 
bars) fused in frame with LacZ reporter gene (yellow bars). pAldC-2336-LacZ does not 
contain the proximal region and the distal region is directly fused to the first non-coding 
exon. 
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Figure 17. -galactosidase assay – line H. -gal immunostaining of whole-mount (A, C) 
and sagittal section (B) of brain from H5 transgenic mice line. (amg: amygdala; h: 
hippocampus; ob: olfactory bulbs). 
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Figure 18.-galactosidase assay – line I. -gal immunostaining of a sagittal section  (A) 
from transgenic mice brain of line I36. Panels B and C show cerebellum and hippocampus 
at a higher magnification (m: medulla, cb: cerebellum, amg: amygdala; h: hippocampus; 
ob: olfactory bulbs; CA1 and CA3 hippocampal neurons; DG: dentate gyrus). 
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Figure 19.-galactosidase assay – line N. -gal immunostaining of whole mount brain 
and cerebellar sagittal section (A) from transgenic mice of line N22. Panels B show a 
higher magnification of the cerebellar sagittal section. (cb: cerebellum, mb: midbrain, h: 
hippocampus; cc:cerebral cortex; ob: olfactory bulbs). 
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3.2.3 Expression analysis of endogenous aldolase C and recombinant -galactosidase 
proteins in brain and cerebellar sections of transgenic mice 
Serial sagittal and horizontal sections of brains from lines H, I and N have been cut and 
immunostained with anti-calbindin and anti aldolase C polyclonal antibodies as positive 
controls. Calbindin is a calcium-binding protein expressed in all Purkinje cells. As already 
described in the Introduction, the endogenous aldolase C is expressed in groups of Purkinje 
cells alternating with non-expressing cells, thus giving rise to the peculiar stripe-like 
pattern, clearly detectable especially when brain slices are cut transversally (Fig. 3) (76). 
We analysed both sagittal (data not shown) and horizontal (Fig. 20, 21, 22) cerebellar 
sections of transgenic mice lines H, I and N by immunohistochemistry, using a polyclonal 
anti--galactosidase antibody, in order to understand if the different deleted regions of 
aldolase C promoter contained in the three LacZ-constructs, were able to drive a stripe-like 
expression of LacZ trangene and hence a peculiar distribution of the hybrid -galactosidase 
protein in the Purkinje cell layer, similar to that of the endogenous aldolase C protein.  
Purkinje cells of mice carrying the pAldC-1464-LacZ construct (line H), which contains 
the smallest fragment of human aldolase C gene promoter (164 bp), were found to be 
immunopositive to -gal, even if its levels were very low and a longer exposure time was 
required for this line, to develop the specific signal (paragraph 2.12) (Fig. 20, panels E-H). 
This result is in agreement with the reduced -gal activity found in the brain of transgenic 
mice from the same line (line H, Fig. 17). The apparent discrepancy between undetectable 
-gal activity in the cerebellum of pAldC-1464-LacZ and the presence of -gal protein in 
the cerebellum of mice carrying the same construct can be ascribed to the greater 
sensitivity of the immunohistochemistry method versus the -gal assays procedure. 
On the contrary, -gal immunoreactivity was very intense in the Purkinje cell layer of mice 
carrying the pAldC-1580-LacZ construct (line I), which contains the proximal promoter 
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region plus the element E of the distal region (Fig. 21, panels E-H). We believe that the 
presence of the element E in this construct makes the difference in terms of 
immunoreactivity levels. USF1 transcription factor binding to this element has been 
previously shown in vitro to be a transcriptional activator (chapter 3.1).  
Similar results were obtained with cerebellar sections from the transgenic mice carrying 
the pAldC-2336-LacZ construct, which contains only the distal region (element E 
included) directly fused to the first non-coding exon of the gene. A mild -gal 
immunoreactivity signal was present in the Purkinje cells of also transgenic mice of line N 
(Fig. 22, panels E-H). 
In all three transgenic mice lines, -gal expression was localized in the cytoplasm of 
groups of stained Purkinje cells (see higher magnification in Figs. 20, 21, 22, panels H, 
thick red arrows) alternating to groups of Purkinje cells don‟t expressing -gal protein 
(Figs. 20, 21, 22,  panels H, thin red arrows). 
Finally, we found that all the three lines show a stripe-like distribution of -galactosidase 
protein in the Purkinje cell layer of the cerebellum, even if, at different extent. These 
results demonstrate that even only the first 164 bp of the human aldolase C gene promoter 
are able to direct striped expression of -gal in the Purkinje cell layer of transgenic mice. 
Probably, the peculiar stripe-like expression of the endogenous aldolase C and of the 
transgene could be also driven by sequence containing the first exon, the first intron and 
the second exon up to the methionine that are present in all three LacZ-constructs. Finally, 
we cannot exclude that also  non-transcriptional event may be involved in stripe-like 
expression of aldolase C in the brain and cerebellum (see Discussion).    
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Figure 20. Calbindin and β-galactosidase immunostaining on horizontal cerebellar 
sections of adult transgenic mice from line H. Anti-calbindin (panels A-D) and anti-β-
gal (panels E-H) immunostaining are shown with increasing magnification of the selected 
cerebellar lobule V (from top to down) from transgenic mice of line H5. β-gal immuno-
positive and immuno-negative cells are indicated with red thick and thin arrows, 
respectively. (gr: granular layer; mol: molecular layer; P: Purkinje cell layer). 
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Figure 21. Calbindin and β-galactosidase immunostaining on horizontal cerebellar 
sections of adult transgenic mice from line I. Anti-calbindin (panels A-D) and anti-β-gal 
(panels E-H) immunostaining are shown with increasing magnification of the selected 
cerebellar lobule V (from top to down) from transgenic mice of line I36. β-gal immuno-
positive and immuno-negative cells are indicated with red thick and thin arrows, 
respectively. (gr: granular layer; mol: molecular layer; P: Purkinje cell layer). 
88 
 
 
Figure 22. Calbindin and β-galactosidase immunostaining on horizontal cerebellar 
sections of adult transgenic mice from line N. Anti-calbindin (panels A-D) and anti-β-
gal (panels E-H) immunostaining are shown with increasing magnification of the selected 
cerebellar lobule V (from top to down) from transgenic mice of line N22. β-gal immuno-
positive and immuno-negative cells are indicated with red thick and thin arrows, 
respectively. (gr: granular layer; mol: molecular layer; P: Purkinje cell layer). 
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3.2.4 Expression analysis of LacZ transgene messenger in adult pAldC-1580-LacZ, 
pAldC-1464-LacZ and pAldC-2336-LacZ transgenic mice 
We analysed LacZ expression levels of at least three different stabilized transgenic mice 
lines for each construct: lines H5, H62, H69, for construct pAldC-1464-LacZ; lines I36, 
I37, I40 for construct pAldC-1580-LacZ; lines N8, N10, N22 for construct  pAldC-2336-
LacZ. 
Among the different lines H, I and N LacZ mRNA levels were expressed at different 
extent. 
Line H (Fig. 23, red bars) showed barely LacZ expression levels in brain and cerebellum 
compared with line B18 (pAldC-2500-LacZ construct) (Fig. 23, blue bars). 
Line I (Fig. 23, violet bars) showed, both in brain and in cerebellum, LacZ expression 
levels 2-fold higher than in B18 line (Fig. 23, blue bars). 
Finally, line N (Fig. 23, green bars) showed LacZ mRNA levels very low in the brain, and 
3.5 fold higher than B18 line in the cerebellum, suggesting that transcriptional regulation 
of LacZ reporter gene in a construct lacking the proximal region is dysregulated. 
As expected, line H obtained with construct pAldC-1464-LacZ containing only 164 bp of 
aldolase C promoter, showed the lowest LacZ expression level. We suggest that this 
proximal promoter region is not responsible of transcription activation but is important for 
a correct transcriptional regulation which results impaired when this region is lacking (see 
line N). 
Line I showed the highest LacZ levels even if the relative pAldC-1580-LacZ construct 
contains only 120 bp more than pAldC-1464-LacZ construct. We believe that this 
transcriptional activation event is due to the presence of Element E binding the 
transcription activator USF1 as we previously demonstrated. 
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These in vivo results are in agreement with those obtained from gal assays and 
immunohistochemistry and strongly validate results obtained from in vitro experiments we 
described in the chapter 3.1.  
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Figure 23. RT-qPCR on cDNA from brain and cerebellum of adult transgenic mice 
from line B, H, I and N. LacZ mRNA expression levels are shown and compared to those 
of B18 line adult mice (blue bars). Red, violet and green bars represent LacZ mRNA levels 
of lines H5, I36 and N22, respectively. Data are presented as the means ± standard 
deviation of three separate experiments.  
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3.3 Functional role of recombinant aldolases 
 
3.3.1 Production of aldolase chimers 
The amino acid sequences of 21 vertebrate aldolase isozymes were previously analyzed to 
identify individual residues specific to each aldolase isozyme (22). Multiple sequence 
alignment revealed a total of 11 aldolase A and 4 aldolase C ISRs (Fig. 24). The 
conservation of ISRs among orthologs implies that they play a role in conferring the 
specific kinetic properties of each isozyme. In the last years, many papers have been 
published by Tolan et al. in which partial and total AB recombinant aldolases have been 
produced. They showed that Km and kcat values of wt aldolase A modified appropriately in 
AB chimera to closely mimic the kinetic parameters of wt aldolase B, thus demonstrating 
that the set of ISRs swapped between the two aldolases, is “necessary and sufficient” for 
determining isozyme-specific kinetic properties (22, 95). Although the location of almost 
all these ISRs on the tertiary and quaternary structures of aldolase was found largely on the 
surface and outside of hydrogen bonding distance to any active site residue, one model is 
that these residues influence kinetic properties at a distance from the active site (22). Long 
distance effects have been documented in other enzymes, such as trypsin (96) and lactate 
dehydrogenase (97).  
In order to test this model and verify the importance of these ISRs in conferring kinetic 
properties to the different isozymes we engineered two mutant enzymes (chimeric 
aldolases) from aldolase A to C (AC aldolase) and from aldolase C to A (CA aldolase). To 
create the AC chimera, the complete set of ISRs from aldolase C isozyme was incorporated 
into the primary sequence of the aldolase A and, at the same time, the ISRs of the aldolase 
A were removed and substituted with the analogous residues in aldolase C. Viceversa, to 
create the CA chimera, we swapped ISRs from aldolase A into C, whereas at the same time 
exchanging the aldolase C ISRs with the analogous residues from aldolase A (Table 1). 
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To accomplish this, PCR-assisted multiple site-directed mutagenesis was used to engineer 
22 nucleotide substitutions in the expression plasmid for wt rabbit aldolase A and 24 
nucleotide substitutions in the expression plasmid for wt human aldolase C. In both the 
cases 15 amino acid substitutions were performed (Table 1). Finally, recombinant 
aldolases were expressed and purified as described in Materials and Methods (paragraphs 
2.16 and 2.17) and subjected to steady-state kinetics. 
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Figure 24. Isozyme-specific residues (ISRs) in vertebrate aldolases.  
Aminoacidic sequences of aldolase A isozymes from various sources were aligned and 
compared with aldolase B and C ISRs. Shaded and open boxes indicate the presence of 
non-conservative and conservative differences paralogous isozyme groups. This figure was 
taken from Pezza J.A. et al. (22). 
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3.3.2 Evaluation of kinetic parameters of chimeric aldolases A/C and C/A 
After expression and purification of AC and CA chimeric aldolases, the steady-state 
kinetics toward the substrate FBP were determined using an enzyme-coupled assay (see 
Materials and Methods, paragraph 2.18).  
By comparing data obtained from AC and CA chimeric aldolases with data obtained from 
wt aldolases A and C (Table 2) we expected that AC chimera should have had a decrease 
in both  Km and kcat values. Both at RT and at 30°C we got a decrease in kcat but not in Km, 
which, on the contrary, showed a significant increase. We concluded that this chimer 
shows an activity severely impaired. As regards CA chimera, we expected it would have 
shown an increase in both  Km and kcat values. Instead, it showed an increase in Km but not 
in kcat (Table 2), so we should conclude that this second chimer seems to work but not 
mimicking aldolase A, as it should be. Relative Lineweaver-Burk plot are shown in 
Figures 25 and 26 where we compared data from AC chimera to those of wt C and data 
from CA chimera to those of wt A aldolase. 
These results show that ISRs we swapped between wt aldolases A and C unfortunately 
seem to be not involved in determining isozyme-specific kinetic properties, or, perhaps 
other, less highly conserved, residues are important. Neverthless, these are very 
preliminary results of experiments that need to be repeated with some modifications at 
protocols and reagents components in order to get higher kcat/Km values not only for 
chimers but also for wt aldolases. In fact, wt aldolases used as control, showed Km values 
similar to those recently published in scientific literature, but kcat  values were too low, thus 
meaning that the efficiency of our catalytic reactions has still to be improved. Furthermore, 
since kinetic properties of wt A and C aldolases are not as different as for A and B 
isozymes, the analysis and the interpretation of data from kinetics of AC and CA 
recombinant aldolases is not so immediate. For this reason we thought it will be very 
useful to look at the activity of chimeric AC and CA aldolases also toward F1P substrate.  
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Steady-State Kinetics of aldolases performed at RT toward FBP 
 Km (x 10
-6
M) kcat (sec
-1
) kcat / Km 
A wt 43±0,8 3,7±0,2 0,086 
C wt 32±0,6 3,6±0,2 0,112 
AC 1335±90 1,66±0,05 0,0012 
CA 135±1,2 1,93±0,04 0,0142 
 
Steady-State Kinetics performed at 30°C toward FBP 
 Km (x 10
-6
M) kcat (sec
-1
) kcat / Km 
A wt 95,9±2,2 7,55±0,2 0,078 
C wt 74±1,0 7,12±0,1 0,096 
AC 6738±300 6,2±0,2 0,0009 
CA 112,5±0,5 3,2±0,1 0,028 
 
Table 2. Km and kcat values of wt and recombinant aldolases, measured at Room 
Temperature and at 30°C. Data represent media±SD of three separate experiments. 
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Figure 25. Lineweaver Burk plot of kinetics from wt and recombinant aldolases 
glycolytic reactions toward FBP substrate. These data were obtained at RT using FBP 
concentration ranging from 2 mM to 10 M for aldolase A wt; from 10 mM to 10 M for 
aldolase C wt; from 10 mM to 50 M for AC chimera; from 3 mM to 10 M for CA 
chimera. 3 g/ml of all enzymes were used. 
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Figure 26. Lineweaver Burk plot of kinetics from wt and recombinant aldolases 
glycolytic reactions toward FBP substrate. These data were obtained at 30°C  using FBP 
concentration ranging from 2 mM to 10 M for aldolase A wt; from 10 mM to 10 M for 
aldolase C wt; from 10 mM to 50 M for AC chimera; from 3 mM to 10 M for CA 
chimera. 3 g/ml of all enzymes were used. 
99 
 
3.4 Aldolase C Knockout mice 
 
3.4.1 Screening of chimeric mice 
As previously described in Materials and Methods, all the steps from ES cells 
electroporation of the aldolase C knock-out construct (Fig. 27) to the production of 
chimeric mice were provided by EMBL from Monterotondo (Rome). 
Once we got chimeric mice, we proceeded by crossing them with wt mice and we screened 
F1 generation for germline transmission by PCR (Fig. 28). 
Primers used for the screening were designed as to amplify two fragments of different size 
in case of positive germline transmission (from wt and floxed alleles of heterozigous F1 
mice) and one only fragment in the opposite case (from the allele of wt F1 generation). 
DNA from chimeric mice (previous step) was used as positive control (Fig. 28, lane 10). 
Unfortunately, none of 375 pups screened, was found to be heterozygous for the floxed 
allele. 
Recently, a new hybrid ES cell line (129 x C57bl/6), which has been shown to be very 
effective in generating highly chimeric animals (frequently fully ES cell-derived), has been 
electroporated with the same construct in order to have a higher probability to generate 
chimeric animals capable of germ line transmission. 
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Figure 27. Aldolase C construct for conditional knockout. 
Neo cassette is located, from 5‟ to 3‟ end, between VII and VI exons. It is flanked by FRT 
sequences (green bars), target of FLP recombinase. Two loxP sequences (yellow bars) are 
located in the II and VI introns, respectively. 
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Figure 28. Screening of F1 generation for germline transmission by PCR. 
Amplification products of genomic DNA random samples from F1 mice (lanes 2-8). All 
DNA singlet represent samples negative to germline transmission (lanes 2-7). The DNA 
doublet is the positive control (lane 10) which has been obtained by amplifying genomic 
DNA from chimeric mice. Size marker, negative control and blank have been loaded in 
lanes 1, 8 and 9, respectively. 
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4.  DISCUSSION 
In the first part of my thesis, we show that human aldolase C gene transcription is 
positively modulated by NGF during PC12 cells neuronal differentiation. Moreover, we 
evidenced a new cis-acting element, element E, in the distal promoter region, which binds 
the transcription factor USF1 both in vitro and in vivo. Interestingly, we found that NGF 
regulation of human aldolase C gene is mainly mediated by USF1 binding to the distal 
promoter region and that phosphorylation events contribute to the activation of USF1 thus 
inducing its binding to DNA. 
USF1 is an ubiquitous transcription factor, member of the upstream stimulatory factor 
(USF) family of transcription factors (98). The protein is characterized by highly 
conserved elements in the C terminal region like the basic region, helix-loop-helix (HLH) 
motif, and, in the case of the human proteins, the C-terminal leucine repeat (LR) (99-101). 
Amino acids 143-197 have been shown to regulate DNA-binding activity in a 
phosphorylation–dependent manner (100). 
The promoters of many neuronal genes have been found to contain the E-box binding USF 
transcription factors. Among these genes we may list: 
the neuron-specific K–Cl cotransporter (KCC2), which has been found to be regulated by 
USF1 in neuroblastoma cell lines and in cortical neurons (102); 
the Machado-Joseph disease gene (MJD), involved in a neurodegenerative disorder caused 
by the expansion of CAG triplet repeats (103); 
the GABABR1a and GABABR1b subunit gene, whose expression is also regulated by 
cAMP in hippocampal neurons (104); 
the calcitonin/calcitonin gene-related neuropeptide gene (CGRP) (105), which has been 
shown to be regulated by USF1 through Ca
2+
 influx after neuronal depolarization and by 
NGF stimulation; 
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the brain-derived neurotrophic factor (BDNF), the nicotinic acetylcholine receptor 7 
subunit (nAchR7), the cyclooxygenase-2 (COX-2) activity-dependent genes, whose 
transcriptional regulation by USF1 has been demonstrated in vivo, suggesting a new 
function for the USFs in the regulation of activity-dependent transcription in neurons of 
CNS (106); 
the rat preprotachykinin A gene (rtPPTA), that has been shown to be responsive to NGF in 
dorsal root ganglion (DRG) neurons (107). 
Finally, in neurons, USF proteins, together with cAMP response element binding (CREB) 
proteins and/or calcium-responsive transcription factors (CaRF) has been shown to activate 
transcription in response to Ca
2+
-activated signaling pathways (104, 108). Particularly, 
USF1/USF2 heterodimer is phosphorylated by Ca
2+
 signaling pathways, such as 
extracellular signal-regulated kinase/mitogen-activated protein kinase, CaM (calmodulin) 
kinase IV and adenylyl cyclase/cAMP-dependent protein kinase, and involved in the 
transcriptional activation through mediation of cAMP-responsive element-binding protein-
binding protein (CBP) (108). These findings are well correlated with what we previously 
evidenced regarding human aldolase C gene transcriptional regulation (44). 
To complement and validate data obtained in vitro from the study of transcriptional 
regulation of human aldolase C gene, we then focused on the analysis of transgenic mice as 
in vivo model to point out the promoter regions responsible for the peculiar brain-specific 
and stripe-like expression of the gene.  
Recently, aldolase C became the most extensively studied marker for antigenic cerebellar 
compartmentation (65, 66). Messenger and protein are expressed by a subset of Purkinje 
cells forming parasagittal stripes in cerebellar transversal AZ and PZ that are highly 
reproducible between individuals and across species (64, 65, 70, 71). An apparent 
correlation among the molecular, morphological and physiological compartments of 
Purkinje cells has been suggested by many authors, for example: aldolase C 
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immunopositive and immunonegative Purkinje cell stripes are shown to correspond to 
afferent and efferent projection patterns, to somatotropic maps revealed by tactile or 
electrical face stimulation, and to molecular layer inhibition evoked by parallel fiber 
stimulation (67, 109-117). The organization of parasagittal Purkinje cell stripes is thought 
to be an intrinsic, cell-autonomous property that is conferred when, or shortly after, these 
cells arise in the subventricular zone of the fourth ventricle (77, 118, 119). 
Correspondingly, particular subsets of parasagittally clustered Purkinje cells were shown to 
have the same birth date (120).  
Possible involvement of cell signaling molecules, including the cell–cell recognition 
molecules cadherin (121) and Eph-ephrin (122) and the reelin receptors Apoer2 and Vldlr 
(123), in the formation of Purkinje cell clusters has been shown.  
Several transcription factors have also been implicated in differential transcriptional 
regulation between Purkinje cell stripes (124, 125). 
Particularly, Sillitoe et al. showed that Engrailed transcription factors (En1 and En2) 
encode positional information that is required for proper organization of the molecular 
properties of the cerebellum (ML molecular coding) in addition to specific anatomical 
divisions of the cerebellum (lobules), and that the two are patterned independently. 
Engrailed homeobox genes thus determine the organization of Purkinje cell sagittal stripe 
gene expression in the adult cerebellum (124).  
Moreover,  Chung et al. found the early B-cell factor 2 (EBF2) transcription factor as one 
of the major responsible of the aldolase C stripe-like expression pattern (125). They 
produced EBF2 null mice and found that aldolase C is uniformly expressed in the 
cerebellar PZ, while it is expressed in stripes in the heterozygote. Several P+ stripe markers 
in the EBF2 null cerebellum show the same ectopic expression pattern as that of aldolase 
C. In contrast, P- stripe markers are expressed relatively normally in the PZ and AZ. They 
concluded that EBF2 acts not only by repressing the aldolase C-positive Purkinje cell 
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phenotype but also regulating the expression of all genes associated with aldolase C+ 
Purkinje cell phenotype. The aldolase C negative Purkinje cell subtype seems to be 
specified independently (125). Unfortunately, this does not explain the persistent stripe-
like expression of aldolase C gene in the AZ of EBF2 null mice.  
However, notwithstanding numerous studies, the complex molecular mechanism 
underlying Purkinje cell stripe formation remains unclear as well as the human gene 
promoter region governing brain- and cell-specific aldolase C expression. 
We have long looked for the key of this peculiar compartment-limited, stripe-like 
expression pattern in the transcriptional regulation of aldolase C gene. This is the reason 
why we produced stabilized transgenic mice lines by using constructs containing different 
deleted regions of human aldolase C gene promoter fused with the transgene LacZ.  
We found that the proximal promoter region (164 bp) of human aldolase C gene is 
responsible for low-levels, brain-specific expression of AldC/LacZ in brain and cerebellum 
of transgenic mice and, for the first time, we evidenced that it is also the minimal promoter 
region sufficient to drive the peculiar stripe-like pattern of the transgene in the Purkinje 
cells. The distal region, including the cis-element E, is responsible for high-levels of 
AldC/LacZ in specific areas of CNS with a stripe-like distribution  in the Purkinje cells. 
Since the first intron and the first non-coding exon sequences of the human gene are 
present in the three constructs carried by all transgenic mice lines, it is also likely that these 
regions are involved in the regulation of the peculiar stripe-like expression pattern of 
aldolase C. 
Moreover, we found consensus sequences specific for EBF2 transcription factor in the 
promoter of human aldolase C gene and of genes that have an identical expression pattern 
to that of aldolase C such as the sphingosine kinase (SPHK) 1a isoform (126), the GABA 
B receptor 2 (GABABR2) (127, 128) and phospholipase C (PLC) b3 (129).  We confirmed 
the binding of EBF2 to the promoter of human aldolase C gene by performing Shift and 
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Supershift Assays (data not shown). Except for EBF specific consensus sequence, no other 
sequence identity was found between the promoter of aldolase C and all the genes that 
show the same stripe-like distribution in the cerebellum . Of course, there should be some 
mechanisms up to the binding of EBF2 to the promoter of aldolase C gene that support 
EBF2 role. We believe that one possible mechanism could be the Notch signaling pathway, 
a clear example of juxtacrine signalling in which two adjacent cells must make physical 
contact in order to communicate (130). Notch could be one of the cell-cell recognition 
molecules leading the formation of Purkinje cell positive and negative clusters, as has 
already been shown for other molecules (cadherins, eph-ephrins and reelin receptors) (121-
123). Notch has a crucial role in cerebellar development and functioning. It has been found 
to interact directly with EBF proteins by inhibiting them, thus diminishing the capacity of 
EBF to bind DNA and down-regulating EBF-regulated promoters (130). 
We hypothesize that the Notch-EBF2-aldolase C pathway could be implicated in the 
induction of the stripe-like expression not only of aldolase C, but also of all the other genes 
showing both an identical and complementar expression pattern, thus contributing to the 
compartmentalization of the cerebellum. Further studies will be conducted to investigate or 
validate the hypothesis we suggested. 
We strongly believe that the cerebellum compartmentalization has a functional 
significance. For this reason we have long intended aldolase C exerting moonlight 
functions besides its glycolytic role. Since it is present in olives and spinal cord in the 
human brain we suggested it could evidentiate an extrapyramidal sensorial transmission 
pathway; it may also have a role in establishing subsets of neurons during cerebellar 
development (64) or during differentiation of progenitor cells in the subventricular zones 
of the developing brain (131). 
Moreover, only recently, the association of aldolase C with a neuronal mRNA was 
uncovered for the first time by Canete-Soler et al. (132). Aldolase C has shown, in vivo, to 
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be the major neurofilament light (NF-L) mRNA binding protein that regulate the stability 
of the transcript by competing with polyA-binding protein (PABP) (133). Particularly, 
aldolase C dimer is a zinc-activated ribonuclease that cleaves the NF-L transcript at sites 
closed to the end-terminal structures and takes part to an important ribonucleoproteic 
complex. PABP shields the NF-L transcript  from aldolase C degradation. Definitively, 
aldolase C and PABP act in conjunction to modulate the levels of NF-L expression in vivo. 
These findings might have important consequences for understanding causal mechanisms 
underlying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) which 
hallmark is the NF accumulation in degenerated motor neurons (133). It is still unknown 
whether the aldolase C uses the same active center for both glycolysis and ribonucleolysis. 
The identification of the active center for the ribonucleolytic activity of aldolase C awaits 
further studies.  
Finally, Funari et al. suggested an additive metabolic role for aldolase C in specific areas 
of brain and cerebellum: since certain neuronal cells perform fructose oxidation and 
aldolase B has never been reported to be expressed in the brain, they suggested aldolase C 
performing fructose metabolism, at least much better than aldolase A according to kinetic 
parameters (134, 135). Related to another potential role for aldolase C, Welsh et al. 
suggested a protective function in combination with the excitatory amino acid transporter, 
EAAT4, that prevents subsets of Purkinje cells from death following global brain ischemia 
(136). This would be consistent with an important endogenous role for fructose 
metabolism in cells expressing aldolase C and is consistent with the documented protective 
effect of dietary fructose in myocardial ischemia/reperfusion injury (136-138). 
Neverthless, the presence of aldolase C in specific brain cells where it is not supported by 
the presence of related enzymes required for fructose metabolism (GLUT transporters, 
ketoexokinase, triokinase) could mean once again that aldolase C may play additional non-
catalytic roles in that cells (135). Based on the peculiar expression pattern of aldolase C 
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and according to Staugaitis et al.(64, 131), Funari et al. also suggested aldolase C exerting 
a role in organizing neuronal circuits (135).  
Why the human body expresses three different forms of aldolase, two of which, aldolase A 
and C, co-localized in some areas of CNS and with very similar glycolytic activities, is not 
yet understood. One of the possibilities is that evolution has allowed redundancy in favor 
of specificity (139, 140) and cells that express one isoform or the other, or isoform 
combinations, may produce complexes that bind and act differently in different cells, at 
different developmental or maturation stages, or in response to different intra/extracellular 
environmental or physiopathological stimuli (141 – 147). 
To improve our knowledge on kinetic parameters of aldolase C versus aldolase A, which 
co-localize in some brain areas and show similar glycolytic activities and to learn more 
about these enzymes from a biochemical point of view, we thought to produce recombinant 
aldolases by swapping ISRs from aldolase A to C and viceversa. Kinetic studies with these 
kind of mutant enzymes, previously conducted by Tolan et al. (22, 95) regarding aldolases 
A and B (AB partial and total chimeras), allowed to understand which are ISRs really 
involved in conformational dynamics of catalytic mechanisms and hence responsible of 
kinetic parameters of aldolases. Our results from kinetic studies of AC and CA chimeras 
are still preliminary and don‟t allow us to draw here significative conclusions. Of course, 
we expected that both the chimers would act relatively to their parent enzyme. As regards 
AC aldolase, we found that this chimer did not work at all, being characterized by a strong 
decrease in affinity toward FBP substrate. Instead, CA chimer showed a good  Km value 
but kcat was lower than we expected. Since kcat values of wt aldolases, used as control, were 
also lower than those published in scientific literature, we need to repeat protein 
preparations and kinetic studies with some protocols modification in order to get better Km 
/ kcat values and hence, more efficient catalytic reactions. 
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Finally, the best way to discover the hypothetic additive functions of aldolase C was, of 
course, the production of a knockout mouse model. The probability to get embryonic 
lethality led us to plan to obtain a conditional rather than conventional knockout mouse.  
Based on aldolase C expression pattern in the brain, we expect to get a mouse model 
characterized by an impaired motor control  or an ataxic gait. Moreover, according to 
Canete-Soler et al. (147) the absence of  ribonucleolytic activity could lead to the 
accumulation of non-degraded NF-L transcripts and to the development of ALS. 
To shed light on the redundant or different functions of co-localized aldolase A and C in 
the brain we also think to produce, in the near future, a knock-in mouse model in which to 
replace aldolase A with C gene. 
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